

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
26 August 2004 (26.08.2004)

PCT

(10) International Publication Number  
**WO 2004/072287 A1**

(51) International Patent Classification<sup>7</sup>: **C12N 15/63**,  
15/861, 1/12, C07K 14/705, C12N 5/10, A61K 48/00

(74) Agent: **BUCHAN, Gavin, MacNicol**; European Patent  
Department, Terlings Park, Eastwick Road, Harlow, Essex  
CM20 2QR (GB).

(21) International Application Number:  
PCT/EP2004/001181

(81) Designated States (*unless otherwise indicated, for every  
kind of national protection available*): AE, AG, AL, AM,  
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,  
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,  
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,  
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,  
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,  
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,  
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,  
ZW.

(22) International Filing Date: 9 February 2004 (09.02.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/447,203 13 February 2003 (13.02.2003) US

(84) Designated States (*unless otherwise indicated, for every  
kind of regional protection available*): ARIPO (BW, GH,  
GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),  
Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), Euro-  
pean (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR,  
GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK,  
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,  
ML, MR, NE, SN, TD, TG).

(71) Applicant (*for all designated States except US*): **ISTI-  
TUTO DI RICERCHE DI BIOLOGIA MOLECO-  
LARE P. ANGELETTI SPA** [IT/IT]; Via Pontina Km.  
30, 600, I-00040 Pomezia (IT).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **AURISICCHIO,**  
**Luigi** [IT/IT]; Irbm, Via Pontina Km. 30, 600, I-00040  
Pomezia (IT). **CILIBERTO, Gennaro** [IT/IT]; Irbm, Via  
Pontina Km. 30, 600, I-00040 Pomezia (IT). **LAHM,**  
**Armin** [DE/IT]; Irbm, Via Pontina Km. 30, 600, I-00040  
Pomezia (IT). **LA MONICA, Nicola** [IT/IT]; Irbm, Via  
Pontina Km. 30, 600, I-00040 Pomezia (IT). **MONACI,**  
**Paolo** [IT/IT]; Irbm, Via Pontina Km. 30, 600, I-00040  
Pomezia (IT). **PALOMBO, Fabio** [IT/IT]; Irbm, Via  
Pontina Km. 30, 600, I-00040 Pomezia (IT).

**Published:**

- *with international search report*
- *before the expiration of the time limit for amending the  
claims and to be republished in the event of receipt of  
amendments*

*For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.*

(54) Title: **RHESUS CARCINO EMBRYONIC ANTIGEN, NUCLEOTIDES ENCODING SAME, AND USES THEREOF**

(57) Abstract: DNAs encoding rhesus monkey carcinoembryonic antigen (rhCEA) have been isolated, cloned and sequenced. The gene encoding CEA is commonly associated with the development of human carcinomas. The present invention provides compositions and methods to elicit or enhance immunity to the protein product expressed by the CEA tumor-associated antigen, wherein aberrant CEA expression is associated with a carcinoma or its development. This invention specifically provides adenoviral vector constructs carrying rhCEA and discloses their use in vaccines and pharmaceutical compositions for preventing and treating cancer.



**WO 2004/072287 A1**

## TITLE OF THE INVENTION

RHESUS CARCINO EMBRYONIC ANTIGEN, NUCLEOTIDES ENCODING SAME, AND USES THEREOF

## FIELD OF THE INVENTION

The present invention relates generally to the therapy of cancer. More specifically, the present invention relates to the rhesus monkey homologue of the tumor associated polypeptide carcinoembryonic antigen, herein designated rhCEA, to isolated nucleic acid molecules which encode this protein, and to recombinant vectors and hosts comprising DNA encoding this protein. This invention also relates to adenoviral vector constructs carrying rhCEA and to their use in vaccines and pharmaceutical compositions for preventing and treating cancer.

## BACKGROUND OF THE INVENTION

The immunoglobulin superfamily (IgSF) consists of numerous genes that code for proteins with diverse functions, one of which is intercellular adhesion. IgSF proteins contain at least one Ig-related domain that is important for maintaining proper intermolecular binding interactions. Because such interactions are necessary to the diverse biological functions of the IgSF members, disruption or aberrant expression of many IgSF adhesion molecules has been correlated with many human diseases.

The carcinoembryonic antigen (CEA) belongs to a subfamily of the Ig superfamily consisting of cell surface glycoproteins. Members of the CEA subfamily are known as CEA-related cell adhesion molecules (CEACAMs). In recent scientific literature, the CEA gene has been renamed CEACAM5, although the nomenclature for the protein remains CEA. Functionally, CEACAMs have been shown to act as both homotypic and heterotypic intercellular adhesion molecules (Benchimol et al., *Cell* 57: 327-334 (1989)). In addition to cell adhesion, CEA inhibits cell death resulting from detachment of cells from the extracellular matrix and can contribute to cellular transformation associated with certain proto-oncogenes such as *Bcl2* and *C-Myc* (see Berinstein, *J. Clin Oncol.* 20(8): 2197-2207 (2002)).

Normal expression of CEA has been detected during fetal development and in adult colonic mucosa. CEA overexpression was first detected in human colon tumors over thirty years ago (Gold and Freedman, *J. Exp. Med.* 121:439-462 (1965)) and has since been found in nearly all colorectal tumors.

Additionally, CEA overexpression is detectable in a high percentage of adenocarcinomas of the pancreas, breast and lung. Because of the prevalence of CEA expression in these tumor types, CEA is widely used clinically in the management and prognosis of these cancers.

The correlation between CEA expression and metastatic growth has also led to its identification as a target for molecular and immunological intervention for colorectal cancer treatment. One therapeutic approach targeting CEA is the use of anti-CEA antibodies (*see* Chester et al., *Cancer Chemother. Pharmacol.* 46 (Suppl): S8-S12 (2000)), while another is to activate the immune system to attack CEA-expressing tumors using CEA-based vaccines (for review, *see* Berinstein, *supra*).

Sequences coding for human CEA have been cloned and characterized (U.S. Patent No. 5,274,087; U.S. Patent No 5,571,710; and U.S. Patent No 5,843,761. See also Beauchemin et al., *Mol. Cell. Biol.* 7:3221-3230 (1987); Zimmerman et al., *Proc. Natl. Acad. Sci. USA* 84:920-924 (1987); Thompson et al. *Proc. Natl. Acad. Sci. USA* 84(9):2965-69 (1987)). Despite the isolation and identification of these CEA genes, it would be desirable to identify additional mammalian genes encoding CEA to allow for the development of a cancer vaccine which is efficacious and not hindered by self-tolerance.

## SUMMARY OF THE INVENTION

The present invention relates to isolated or purified nucleic acid molecules (polynucleotides) comprising a sequence of nucleotides that encode a novel rhesus monkey carcino embryonic antigen (hereinafter rhCEA) as set forth in SEQ ID NO:2 and SEQ ID NO:18. The DNA molecules disclosed herein may be transfected into a host cell of choice wherein the recombinant host cell provides a source for substantial levels of an expressed functional rhCEA protein (SEQ ID NO:2 and SEQ ID NO:18).

The present invention further relates to an isolated nucleic acid molecule which encodes mRNA that expresses a novel rhesus monkey CEA protein; this DNA molecule comprising the nucleotide sequence disclosed herein as SEQ ID NO:1. Nucleotide sequences coding for rhesus CEA are herein designated rhCEACAM5. A preferred aspect of this portion of the present invention is disclosed in FIGURE 1A, which shows a DNA molecule (SEQ ID NO:1) that encodes a novel rhCEA protein (SEQ ID NO:2).

Another aspect of this invention is an isolated nucleic acid molecule which encodes a novel rhesus monkey CEA protein (SEQ ID NO:18), said nucleic acid molecule comprising a sequence of nucleotides as shown in FIGURE 1B and as set forth in SEQ ID NO:5.

The present invention also relates to recombinant vectors and recombinant host cells, both prokaryotic and eukaryotic, which contain the nucleic acid molecules disclosed throughout this specification.

The present invention further relates to a process for expressing a rhesus monkey CEA protein in a recombinant host cell, comprising: (a) introducing a vector comprising a nucleic acid as set forth in SEQ ID NO:1 or SEQ ID NO:5 into a suitable host cell; and, (b) culturing the host cell under conditions which allow expression of said rhesus monkey CEA protein.

A preferred aspect of the present invention is a substantially purified form of a rhesus monkey CEA protein which consists of the amino acid sequence disclosed in FIGURE 2A (SEQ ID NO:2).

Another preferred aspect of the present invention is a substantially purified form of a rhesus monkey CEA protein which consists of the amino acid sequence disclosed in FIGURE 2B (SEQ ID NO:18).

Another preferred aspect of the present invention relates to a substantially purified, fully processed (including proteolytic processing, glycosylation and/or phosphorylation), mature rhCEA protein obtained from a recombinant host cell containing a DNA expression vector comprising nucleotide sequence as set forth in SEQ ID NO:1 or SEQ ID NO:5, which express the rhCEA protein. It is especially preferred that the recombinant host cell be a eukaryotic host cell, such as a mammalian cell line.

Yet another aspect of this invention is a method of preventing or treating cancer comprising administering to a mammal a vaccine vector comprising an isolated nucleic acid molecule, the isolated nucleic acid molecule comprising a sequence of nucleotides that encodes a rhesus monkey carcinoembryonic antigen (rhCEA) protein as set forth in SEQ ID NO:2 or SEQ ID NO:18.

The present invention further relates to an adenovirus vaccine vector comprising an adenoviral genome with a deletion in the E1 region, and an insert in the E1 region, wherein the insert comprises an expression cassette comprising: (a) a

polynucleotide encoding a rhesus monkey CEA protein; and (b) a promoter operably linked to the polynucleotide.

The present invention also relates to a vaccine plasmid comprising a plasmid portion and an expression cassette portion, the expression cassette portion comprising: (a) a polynucleotide encoding a rhesus monkey CEA protein; and (b) a promoter operably linked to the polynucleotide.

Another aspect of the present invention is a method of protecting or a mammal from cancer or treating a mammal suffering from cancer comprising: (a) introducing into the mammal a first vector comprising: i) a polynucleotide encoding a rhesus monkey CEA protein; and ii) a promoter operably linked to the polynucleotide; (b) allowing a predetermined amount of time to pass; and (c) introducing into the mammal a second vector comprising: i) a polynucleotide encoding a rhesus monkey CEA protein; and ii) a promoter operably linked to the polynucleotide.

As used throughout the specification and in the appended claims, the singular forms "a," "an," and "the" include the plural reference unless the context clearly dictates otherwise.

As used throughout the specification and appended claims, the following definitions and abbreviations apply:

The term "promoter" refers to a recognition site on a DNA strand to which the RNA polymerase binds. The promoter forms an initiation complex with RNA polymerase to initiate and drive transcriptional activity. The complex can be modified by activating sequences termed "enhancers" or inhibiting sequences termed "silencers".

The term "cassette" refers to the sequence of the present invention that contains the nucleic acid sequence which is to be expressed. The cassette is similar in concept to a cassette tape; each cassette has its own sequence. Thus by interchanging the cassette, the vector will express a different sequence. Because of the restriction sites at the 5' and 3' ends, the cassette can be easily inserted, removed or replaced with another cassette.

The term "vector" refers to some means by which DNA fragments can be introduced into a host organism or host tissue. There are various types of vectors including plasmid, virus (including adenovirus), bacteriophages and cosmids.

The term "first generation," as used in reference to adenoviral vectors, describes said adenoviral vectors that are replication-defective. First generation adenovirus vectors typically have a deleted or inactivated E1 gene region, and preferably have a deleted or inactivated E3 gene region.

The designation "pV1J-rhCEA" refers to a plasmid construct disclosed herein comprising the human CMV immediate-early (IE) promoter with intron A, a full-length rhesus CEA gene, bovine growth hormone-derived polyadenylation and transcriptional termination sequences, and a minimal pUC backbone.

The designations "pMRK-Ad5-rhCEA" and "MRK-rhCEA" refer to a construct, disclosed herein, which comprises an Ad5 adenoviral genome deleted of the E1 and E3 regions. In this plasmid, the E1 region is replaced by a rhesus CEA gene in an E1 parallel orientation under the control of a human CMV promoter without intron A, followed by a bovine growth hormone polyadenylation signal.

The designation "pBS-rhCEA" refers to a construct disclosed herein comprising the pBluescriptII KS (+) plasmid and a full-length rhCEA gene.

The term "effective amount" means sufficient vaccine composition is introduced to produce the adequate levels of the polypeptide, so that an immune response results. One skilled in the art recognizes that this level may vary.

"Substantially free from other nucleic acids" means at least 90%, preferably 95%, more preferably 99%, and even more preferably 99.9%, free of other nucleic acids. As used interchangeably, the terms "substantially free from other nucleic acids," "substantially purified," "isolated nucleic acid" or "purified nucleic acid" also refer to DNA molecules which comprise a coding region for a rhesus CEA protein that has been purified away from other cellular components. Thus, a rhesus CEA DNA preparation that is substantially free from other nucleic acids will contain, as a percent of its total nucleic acid, no more than 10%, preferably no more than 5%, more preferably no more than 1%, and even more preferably no more than 0.1%, of non-rhesus CEA nucleic acids. Whether a given rhesus CEA DNA preparation is substantially free from other nucleic acids can be determined by such conventional techniques of assessing nucleic acid purity as, *e.g.*, agarose gel electrophoresis combined with appropriate staining methods, *e.g.*, ethidium bromide staining, or by sequencing.

"Substantially free from other proteins" or "substantially purified" means at least 90%, preferably 95%, more preferably 99%, and even more preferably 99.9%, free of other proteins. Thus, a rhesus monkey CEA protein preparation that is

substantially free from other proteins will contain, as a percent of its total protein, no more than 10%, preferably no more than 5%, more preferably no more than 1%, and even more preferably no more than 0.1%, of non-rhesus monkey CEA proteins. Whether a given rhesus monkey CEA protein preparation is substantially free from other proteins can be determined by such conventional techniques of assessing protein purity as, *e.g.*, sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) combined with appropriate detection methods, *e.g.*, silver staining or immunoblotting.

As used interchangeably, the terms “substantially free from other proteins” or “substantially purified,” or “isolated rhesus monkey CEA protein” or “purified rhesus monkey CEA protein” also refer to rhesus monkey CEA protein that has been isolated from a natural source. Use of the term “isolated” or “purified” indicates that rhesus monkey CEA protein has been removed from its normal cellular environment. Thus, an isolated rhesus monkey CEA protein may be in a cell-free solution or placed in a different cellular environment from that in which it occurs naturally. The term isolated does not imply that an isolated rhesus monkey CEA protein is the only protein present, but instead means that an isolated rhCEA protein is substantially free of other proteins and non-amino acid material (*e.g.*, nucleic acids, lipids, carbohydrates) naturally associated with the rhCEA protein *in vivo*. Thus, a rhesus monkey CEA protein that is recombinantly expressed in a prokaryotic or eukaryotic cell and substantially purified from this host cell which does not naturally (*i.e.*, without intervention) express this rhCEA protein is of course “isolated rhesus monkey CEA protein” under any circumstances referred to herein. As noted above, a rhCEA protein preparation that is an isolated or purified rhCEA protein will be substantially free from other proteins and will contain, as a percent of its total protein, no more than 10%, preferably no more than 5%, more preferably no more than 1%, and even more preferably no more than 0.1%, of non-rhesus monkey CEA proteins.

A “conservative amino acid substitution” refers to the replacement of one amino acid residue by another, chemically similar, amino acid residue. Examples of such conservative substitutions are: substitution of one hydrophobic residue (isoleucine, leucine, valine, or methionine) for another; substitution of one polar residue for another polar residue of the same charge (*e.g.*, arginine for lysine; glutamic acid for aspartic acid).

“rhCEA” refers to a rhesus monkey carcinoembryonic antigen.

The term "mammalian" refers to any mammal, including a human being.

The abbreviation "Ag" refers to an antigen.

The abbreviations "Ab" and "mAb" refer to an antibody and a monoclonal antibody, respectively.

The abbreviation "ORF" refers to the open reading frame of a gene.

#### BRIEF DESCRIPTION OF THE DRAWINGS

FIGURE 1 shows nucleotide sequences of the rhesus monkey CEA cDNA molecules, as set forth in SEQ ID NO:1 (Panel A) and SEQ ID NO:5 (Panel B). *See* EXAMPLE 2.

FIGURE 2 shows the predicted amino acid sequences of the first rhesus monkey CEA protein, as set forth in SEQ ID NO:2 (Panel A) and the second rhesus monkey CEA protein, as set forth in SEQ ID NO:18 (Panel B). The two amino acid differences between the first and the second rhesus CEA proteins are bold and underlined in Panel B.

FIGURE 3 shows an alignment of the 5' untranslated region of human CEACAM family members. Sequences shown were compared and used to design degenerate primers as described in EXAMPLE 2. Nucleotides that are the same as the corresponding nucleotide in other CEACAM family members are highlighted. Dashes indicate that spaces were added to facilitate alignment of the sequences. Nucleotide number of each cDNA sequence, as disclosed in GenBank, is shown in parentheses.

FIGURE 4 shows the expression of the rhesus CEA protein. HeLa cells were transfected with phagemids obtained by screening the lambda-CEA library and a western blot was performed using a rabbit polyclonal antibody vs. human CEA protein. Expression of 2 clones out of 15 is shown.

FIGURE 5 shows a schematic representation of the rhesus CEA coding region. Internal repetitions are indicated and restriction sites for gene fragmentation and sequence are reported.

FIGURE 6 shows an alignment of the human (SEQ ID NO:6) and rhesus (SEQ ID NO:1) CEACAM-5 nucleotide sequences. Nucleotides that are different between the two CEACAM-5 sequences are shown in bold.



FIGURE 7 shows an alignment of the human (SEQ ID NO:7) and rhesus (SEQ ID NO:2) CEACAM-5 open reading frames. Amino acids that are different between the two CEACAM-5 sequences are shown in bold.

FIGURE 8 shows the humoral response against human CEA in CEA transgenic mice. The average antibody titer is given for two groups of mice: one immunized with rhesus CEA and one immunized with human CEA (EXAMPLE 7).

FIGURE 9 shows the cell mediated immune response against human CEA in CEA transgenic mice. CEA transgenic mice were vaccinated either with hCEA expressing vectors or with rhCEA expressing vectors (EXAMPLE 9).

FIGURE 10 shows the cell mediated immune response against rhesus CEA peptides in CEA transgenic mice immunized with rhesus or human CEA.

#### DETAILED DESCRIPTION OF THE INVENTION

The gene encoding the carcinoembryonic antigen (CEA) is commonly associated with the development of adenocarcinomas. The present invention relates to compositions and methods to elicit or enhance immunity to the protein product expressed by the CEA tumor-associated antigen, wherein aberrant CEA expression is associated with the carcinoma or its development. Association of aberrant CEA expression with a carcinoma does not require that the CEA protein be expressed in tumor tissue at all timepoints of its development, as abnormal CEA expression may be present at tumor initiation and not be detectable late into tumor progression or vice-versa.

To this end, polynucleotides encoding rhesus monkey carcinoembryonic antigen (rhCEA) are provided. The molecules of the present invention may be used in a recombinant adenovirus or plasmid-based vaccine to provide effective immunoprophylaxis against adenocarcinomas through cell-mediated immunity. When directly introduced into a vertebrate *in vivo*, the invention polynucleotides induce the expression of encoded proteins within the animal, including mammals such as primates, dogs and humans.

The present invention relates to an isolated nucleic acid molecule (polynucleotide) comprising a sequence of nucleotides which encodes mRNA that expresses a novel rhCEA protein as set forth in SEQ ID NO:2 or SEQ ID NO:18. The nucleic acid molecules of the present invention are substantially free from other nucleic acids.

The isolated nucleic acid molecules of the present invention may include a deoxyribonucleic acid molecule (DNA), such as genomic DNA and complementary DNA (cDNA), which may be single (coding or noncoding strand) or double stranded, as well as synthetic DNA, such as a synthesized, single stranded polynucleotide. The isolated nucleic acid molecules of the present invention may also include a ribonucleic acid molecule (RNA). For most cloning purposes, DNA is a preferred nucleic acid.

A preferred DNA molecule of the present invention comprises the nucleotide sequence disclosed herein as SEQ ID NO:1, shown in FIGURE 1A, which encodes the rhesus CEA protein shown in FIGURE 2A and set forth as SEQ ID NO:2.

Another preferred DNA molecule of the present invention comprises the nucleotide sequence disclosed herein as SEQ ID NO:5 (hereinafter "second rhCEA" DNA sequence), shown in FIGURE 1B, which encodes the rhesus CEA protein shown in FIGURE 2B and set forth as SEQ ID NO:18. These rhCEA nucleic acid molecules were identified through RT-PCR as described in detail in EXAMPLE 2. The second rhCEA DNA sequence (SEQ ID NO:5) differs from the first by two nucleotides and was cloned from colon tissue from a different rhesus monkey. This DNA sequence codes for a rhesus CEA protein that differs from the first rhesus CEA protein by two amino acids.

The isolated cDNA clones, associated vectors, hosts, recombinant subcellular fractions and membranes, and the expressed and mature forms of rhCEA are useful for the development of a cancer vaccine.

The present invention also includes biologically active fragments or mutants of SEQ ID NOs:1 or 5, which encode mRNA expressing novel rhCEA proteins. Any such biologically active fragment and/or mutant will encode either a protein or protein fragment which at least substantially mimics the pharmacological properties of the rhCEA protein, including but not limited to the rhCEA protein as set forth in SEQ ID NO:2 or SEQ ID NO:18. Any such polynucleotide includes but is not necessarily limited to: nucleotide substitutions, deletions, additions, amino-terminal truncations and carboxy-terminal truncations. The mutations of the present invention encode mRNA molecules that express a functional rhCEA protein in a eukaryotic cell so as to be useful in cancer vaccine development.

This invention also relates to synthetic DNA that encodes the rhCEA protein where the nucleotide sequence of the synthetic DNA differs significantly from the nucleotide sequence of SEQ ID NO:1 and SEQ ID NO:5, but still encodes the rhCEA protein as set forth in SEQ ID NO:2 or SEQ ID NO:18. Such synthetic DNAs are intended to be within the scope of the present invention.

Therefore, the present invention discloses codon redundancy that may result in numerous DNA molecules expressing an identical protein. For purposes of this specification, a sequence bearing one or more replaced codons will be defined as a degenerate variation. Also included within the scope of this invention are mutations either in the DNA sequence or the translated protein that do not substantially alter the ultimate physical properties of the expressed protein. For example, substitution of valine for leucine, arginine for lysine, or asparagine for glutamine may not cause a change in the functionality of the polypeptide.

It is known that DNA sequences coding for a peptide may be altered so as to code for a peptide that has properties that are different than those of the naturally occurring peptide. Methods of altering the DNA sequences include but are not limited to site directed mutagenesis. Examples of altered properties include but are not limited to changes in the affinity of an enzyme for a substrate or receptor for a ligand.

Included in the present invention are DNA sequences that hybridize to SEQ ID NO:1 or SEQ ID NO:5 under stringent conditions. By way of example, and not limitation, a procedure using conditions of high stringency is as follows: Prehybridization of filters containing DNA is carried out for 2 hours to overnight at 65°C in buffer composed of 6X SSC, 5X Denhardt's solution, and 100 µg/ml denatured salmon sperm DNA. Filters are hybridized for 12 to 48 hrs at 65°C in prehybridization mixture containing 100 µg/ml denatured salmon sperm DNA and 5-20 X 10<sup>6</sup> cpm of <sup>32</sup>P-labeled probe. Washing of filters is done at 37°C for 1 hr in a solution containing 2X SSC, 0.1% SDS. This is followed by a wash in 0.1X SSC, 0.1% SDS at 50°C for 45 min. before autoradiography. Other procedures using conditions of high stringency would include either a hybridization step carried out in 5XSSC, 5X Denhardt's solution, 50% formamide at 42°C for 12 to 48 hours or a washing step carried out in 0.2X SSPE, 0.2% SDS at 65°C for 30 to 60 minutes.

Reagents mentioned in the foregoing procedures for carrying out high stringency hybridization are well known in the art. Details of the composition of these reagents can be found in, e.g., Sambrook et al., *Molecular Cloning: A*

*Laboratory Manual*; Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, 1989, which is hereby incorporated by reference. In addition to the foregoing, other conditions of high stringency which may be used are well known in the art.

A preferred aspect of the present invention is a substantially purified form of a rhesus monkey CEA protein which comprises a sequence of amino acids as disclosed in FIGURE 2A (SEQ ID NO:2).

Another preferred aspect of the present invention is a substantially purified form of a rhesus monkey CEA protein which comprises a sequence of amino acids as disclosed in FIGURE 2B (SEQ ID NO:18).

This invention also relates to various functional domains of rhCEA and to hybrid molecules comprising at least one of these sequences. The CEA protein comprises an amino-terminal domain with a processed leader sequence and a hydrophobic carboxy-terminal domain. CEA also comprises three Ig-like internal domains. Subdomains of the N-terminal domain were shown by Taheri et al. (*J. Biol. Chem.* 275(35): 26935-26943 (2000)) to be required for CEA's intercellular adhesion function.

The present invention also includes biologically active fragments and/or mutants of a rhCEA protein, comprising the amino acid sequence as set forth in SEQ ID NO: 2 or SEQ ID NO:18, including but not necessarily limited to amino acid substitutions, deletions, additions, amino terminal truncations and carboxy-terminal truncations such that these mutations provide for proteins or protein fragments of diagnostic, therapeutic or prophylactic use and would be useful for cancer vaccine development.

The rhesus monkey CEA proteins of the present invention may be in the form of the "mature" protein or may be a part of a larger protein such as a fusion protein. It is often advantageous to include an additional amino acid sequence which contains secretory or leader sequences, pro-sequences, sequences which aid in purification such as multiple histidine residues, or an additional sequence for stability during recombinant production.

The present invention also relates to rhCEA fusion constructs, including but not limited to fusion constructs which express a portion of the rhesus CEA protein linked to various markers, including but in no way limited to GFP (Green fluorescent protein), the MYC epitope, GST, and Fc. Any such fusion construct may be expressed in the cell line of interest and used to screen for

modulators of the rhesus CEA protein disclosed herein. Also contemplated are fusion constructs that are constructed to enhance the immune response to rhesus CEA including, but not limited to: DOM and hsp70.

The present invention further relates to recombinant vectors that comprise the substantially purified nucleic acid molecules disclosed throughout this specification. These vectors may be comprised of DNA or RNA. For most cloning purposes, DNA vectors are preferred. Typical vectors include plasmids, modified viruses, bacteriophage, cosmids, yeast artificial chromosomes, and other forms of episomal or integrated DNA that can encode a rhCEA protein. It is well within the purview of the skilled artisan to determine an appropriate vector for a particular gene transfer or other use.

An expression vector containing DNA encoding a rhCEA protein may be used for expression of rhCEA in a recombinant host cell. Expression vectors may include, but are not limited to, cloning vectors, modified cloning vectors, specifically designed plasmids or viruses. Also, a variety of bacterial expression vectors may be used to express recombinant rhCEA in bacterial cells if desired. In addition, a variety of fungal cell expression vectors may be used to express recombinant rhCEA in fungal cells. Further, a variety of insect cell expression vectors may be used to express recombinant protein in insect cells.

The present invention also relates to host cells transformed or transfected with vectors comprising the nucleic acid molecules of the present invention. Recombinant host cells may be prokaryotic or eukaryotic, including but not limited to, bacteria such as *E. coli*, fungal cells such as yeast, mammalian cells including, but not limited to, cell lines of bovine, porcine, monkey and rodent origin; and insect cells including but not limited to *Drosophila* and silkworm derived cell lines. Such recombinant host cells can be cultured under suitable conditions to produce rhCEA or a biologically equivalent form.

As noted above, an expression vector containing DNA encoding a rhCEA protein may be used for expression of rhCEA in a recombinant host cell. Therefore, another aspect of this invention is a process for expressing a rhesus monkey CEA protein in a recombinant host cell, comprising: (a) introducing a vector comprising a nucleic acid as set forth in SEQ ID NO:1 or SEQ ID NO:5 into a suitable host cell; and, (b) culturing the host cell under conditions which allow expression of said rhesus monkey CEA protein.

Following expression of rhCEA in a host cell, rhCEA protein may be recovered to provide rhCEA protein in active form. Several rhCEA protein purification procedures are available and suitable for use. Recombinant rhCEA protein may be purified from cell lysates and extracts by various combinations of, or individual application of salt fractionation, ion exchange chromatography, size exclusion chromatography, hydroxylapatite adsorption chromatography and hydrophobic interaction chromatography. In addition, recombinant rhCEA protein can be separated from other cellular proteins by use of an immunoaffinity column made with monoclonal or polyclonal antibodies specific for full-length rhCEA protein, or polypeptide fragments of rhCEA protein.

The nucleic acids of the present invention may be assembled into an expression cassette which comprises sequences designed to provide for efficient expression of the protein in a human cell. The cassette preferably contains the full-length rhCEA gene, with related transcriptional and translations control sequences operatively linked to it, such as a promoter, and termination sequences. In a preferred embodiment, the promoter is the cytomegalovirus promoter without the intron A sequence (CMV), although those skilled in the art will recognize that any of a number of other known promoters such as the strong immunoglobulin, or other eukaryotic gene promoters may be used. A preferred transcriptional terminator is the bovine growth hormone terminator, although other known transcriptional terminators may also be used. The combination of CMV-BGH terminator is particularly preferred.

In accordance with this invention, the rhesus CEA expression cassette is inserted into a vector. The vector is preferably an adenoviral vector, although linear DNA linked to a promoter, or other vectors, such as adeno-associated virus or a modified vaccinia virus, retroviral or lentiviral vector may also be used.

If the vector chosen is an adenovirus, it is preferred that the vector be a so-called first-generation adenoviral vector. These adenoviral vectors are characterized by having a non-functional E1 gene region, and preferably a deleted adenoviral E1 gene region. In some embodiments, the expression cassette is inserted in the position where the adenoviral E1 gene is normally located. In addition, these vectors optionally have a non-functional or deleted E3 region. It is preferred that the adenovirus genome used be deleted of both the E1 and E3 regions ( $\Delta E1\Delta E3$ ). The

adenoviruses can be multiplied in known cell lines which express the viral E1 gene, such as 293 cells, or PERC.6 cells, or in cell lines derived from 293 or PERC.6 cell which are transiently or stably transformed to express an extra protein. For examples, when using constructs that have a controlled gene expression, such as a tetracycline regulatable promoter system, the cell line may express components involved in the regulatory system. One example of such a cell line is T-Rex-293; others are known in the art.

For convenience in manipulating the adenoviral vector, the adenovirus may be in a shuttle plasmid form. This invention is also directed to a shuttle plasmid vector which comprises a plasmid portion and an adenovirus portion, the adenovirus portion comprising an adenoviral genome which has a deleted E1 and optional E3 deletion, and has an inserted expression cassette comprising rhesus CEA. In preferred embodiments, there is a restriction site flanking the adenoviral portion of the plasmid so that the adenoviral vector can easily be removed. The shuttle plasmid may be replicated in prokaryotic cells or eukaryotic cells.

In a preferred embodiment of the invention, the expression cassette is inserted into the pMRKAd5-HV0 adenovirus plasmid (*See Emini et al.*, WO 02/22080, which is hereby incorporated by reference). This plasmid comprises an Ad5 adenoviral genome deleted of the E1 and E3 regions. The design of the pMRKAd5-HV0 plasmid was improved over prior adenovectors by extending the 5' cis-acting packaging region further into the E1 gene to incorporate elements found to be important in optimizing viral packaging, resulting in enhanced virus amplification. Advantageously, this enhanced adenoviral vector is capable of maintaining genetic stability following high passage propagation.

Standard techniques of molecular biology for preparing and purifying DNA constructs enable the preparation of the adenoviruses, shuttle plasmids, and DNA immunogens of this invention.

The vectors described above may be used in immunogenic compositions and vaccines for preventing the development of adenocarcinomas associated with aberrant CEA expression and/or for treating existing cancers. To this end, one aspect of the instant invention is a method of preventing or treating cancer comprising administering to a mammal a vaccine vector comprising an isolated nucleic acid molecule, the isolated nucleic acid molecule comprising a sequence of

nucleotides that encodes a rhesus monkey CEA protein as set forth in SEQ ID NO:2 or SEQ ID NO:18.

In accordance with the method described above, the vaccine vector may be administered for the treatment or prevention of cancer in any mammal. In a preferred embodiment of the invention, the mammal is a human.

Further, one of skill in the art may choose any type of vector for use in the treatment and prevention method described. Preferably, the vector is an adenovirus vector or a plasmid vector. In a preferred embodiment of the invention, the vector is an adenoviral vector comprising an adenoviral genome with a deletion in the adenovirus E1 region, and an insert in the adenovirus E1 region, wherein the insert comprises an expression cassette comprising: (a) a polynucleotide encoding a rhesus monkey CEA protein; and (b) a promoter operably linked to the polynucleotide.

The instant invention further relates to an adenovirus vaccine vector comprising an adenoviral genome with a deletion in the E1 region, and an insert in the E1 region, wherein the insert comprises an expression cassette comprising: (a) a polynucleotide encoding a rhesus monkey CEA protein; and (b) a promoter operably linked to the polynucleotide.

In a preferred embodiment of this aspect of the invention, the adenovirus vector is an Ad 5 vector.

In another preferred embodiment of the invention, the adenovirus vector is an Ad 6 vector.

In another aspect, the invention relates to a vaccine plasmid comprising a plasmid portion and an expression cassette portion, the expression cassette portion comprising: (a) a polynucleotide encoding a rhesus monkey CEA protein; and (b) a promoter operably linked to the polynucleotide.

In some embodiments of this invention, the recombinant adenovirus vaccines disclosed herein are used in various prime/boost combinations with a plasmid-based polynucleotide vaccine in order to induce an enhanced immune response. In this case, the two vectors are administered in a "prime and boost" regimen. For example the first type of vector is administered, then after a predetermined amount of time, for example, 1 month, 2 months, six months, or other appropriate interval, a second type of vector is administered. Preferably the vectors carry expression cassettes encoding the same polynucleotide or combination of



polynucleotides. In the embodiment where a plasmid DNA is also used, it is preferred that the vector contain one or more promoters recognized by mammalian or insect cells. In a preferred embodiment, the plasmid would contain a strong promoter such as, but not limited to, the CMV promoter. The rhesus CEA gene or other gene to be expressed would be linked to such a promoter. An example of such a plasmid would be the mammalian expression plasmid V1Jns as described (J. Shiver *et. al.* in *DNA Vaccines*, M. Liu et al. eds., N.Y. Acad. Sci., N.Y., 772:198-208 (1996), which is herein incorporated by reference).

As stated above, an adenoviral vector vaccine and a plasmid vaccine may be administered to a vertebrate as part of a single therapeutic regime to induce an immune response. To this end, the present invention relates to a method of protecting a mammal from cancer comprising: (a) introducing into the mammal a first vector comprising: i) a polynucleotide encoding a rhesus monkey CEA protein; and ii) a promoter operably linked to the polynucleotide; (b) allowing a predetermined amount of time to pass; and (c) introducing into the mammal a second vector comprising: i) a polynucleotide encoding a rhesus monkey CEA protein; and ii) a promoter operably linked to the polynucleotide.

In one embodiment of the method of protection described above, the first vector is a plasmid and the second vector is an adenovirus vector. In an alternative embodiment, the first vector is an adenovirus vector and the second vector is a plasmid.

The instant invention further relates to a method of treating a mammal suffering from an adenocarcinoma comprising: (a) introducing into the mammal a first vector comprising: i) a polynucleotide encoding a rhesus monkey CEA protein; and ii) a promoter operably linked to the polynucleotide; (b) allowing a predetermined amount of time to pass; and (c) introducing into the mammal a second vector comprising: i) a polynucleotide encoding a rhesus monkey CEA protein; and ii) a promoter operably linked to the polynucleotide.

In one embodiment of the method of treatment described above, the first vector is a plasmid and the second vector is an adenovirus vector. In an alternative embodiment, the first vector is an adenovirus vector and the second vector is a plasmid.

The amount of expressible DNA or transcribed RNA to be introduced into a vaccine recipient will depend partially on the strength of the promoters used and on the immunogenicity of the expressed gene product. In general, an

immunologically or prophylactically effective dose of about 1 ng to 100 mg, and preferably about 10 µg to 300 µg of a plasmid vaccine vector is administered directly into muscle tissue. An effective dose for recombinant adenovirus is approximately  $10^6 - 10^{12}$  particles and preferably about  $10^7 - 10^{11}$  particles. Subcutaneous injection, intradermal introduction, impression through the skin, and other modes of administration such as intraperitoneal, intravenous, or inhalation delivery are also contemplated. It is also contemplated that booster vaccinations may be provided. Parenteral administration, such as intravenous, intramuscular, subcutaneous or other means of administration with adjuvants such as interleukin 12 protein, concurrently with or subsequent to parenteral introduction of the vaccine of this invention is also advantageous.

The vaccine vectors of this invention may be naked, i.e., unassociated with any proteins, adjuvants or other agents which impact on the recipient's immune system. In this case, it is desirable for the vaccine vectors to be in a physiologically acceptable solution, such as, but not limited to, sterile saline or sterile buffered saline. Alternatively, it may be advantageous to administer an immunostimulant, such as an adjuvant, cytokine, protein, or other carrier with the vaccines or immunogenic compositions of the present invention. Therefore, this invention includes the use of such immunostimulants in conjunction with the compositions and methods of the present invention. An immunostimulant, as used herein, refers to essentially any substance that enhances or potentiates an immune response (antibody and/or cell-mediated) to an exogenous antigen. Said immunostimulants can be administered in the form of DNA or protein. Any of a variety of immunostimulants may be employed in conjunction with the vaccines and immunogenic compositions of the present inventions, including, but not limited to: GM-CSF, IFN $\alpha$ , tetanus toxoid, IL12, B7.1, LFA-3 and ICAM-1. Said immunostimulants are well-known in the art. Agents which assist in the cellular uptake of DNA, such as, but not limited to calcium ion, may also be used. These agents are generally referred to as transfection facilitating reagents and pharmaceutically acceptable carriers. Those of skill in the art will be able to determine the particular immunostimulant or pharmaceutically acceptable carrier as well as the appropriate time and mode of administration.

Any of a variety of procedures may be used to clone rhCEA. These methods include, but are not limited to, (1) a RACE PCR cloning technique (Frohman et al., *Proc. Natl. Acad. Sci. USA* 85: 8998-9002 (1988)). 5' and/or 3' RACE may be

performed to generate a full-length cDNA sequence. This strategy involves using gene-specific oligonucleotide primers for PCR amplification of rhCEA cDNA. These gene-specific primers are designed through identification of an expressed sequence tag (EST) nucleotide sequence which has been identified by searching any number of publicly available nucleic acid and protein databases; (2) direct functional expression of the rhCEA cDNA following the construction of a rhCEA-containing cDNA library in an appropriate expression vector system; (3) screening an rhCEA-containing cDNA library constructed in a bacteriophage or plasmid shuttle vector with a labeled degenerate oligonucleotide probe designed from the amino acid sequence of the rhCEA protein; (4) screening an rhCEA-containing cDNA library constructed in a bacteriophage or plasmid shuttle vector with a partial cDNA encoding the rhCEA protein. This partial cDNA is obtained by the specific PCR amplification of rhCEA DNA fragments through the design of degenerate oligonucleotide primers from the amino acid sequence known for other membrane proteins which are related to the rhCEA protein; (5) screening a rhCEA-containing cDNA library constructed in a bacteriophage or plasmid shuttle vector with a partial cDNA or oligonucleotide with homology to a mammalian rhCEA protein. This strategy may also involve using gene-specific oligonucleotide primers for PCR amplification of rhCEA cDNA identified as an EST as described above; or (6) designing 5' and 3' gene specific oligonucleotides using SEQ ID NO: 1 as a template so that either the full-length cDNA may be generated by known RACE techniques, or a portion of the coding region may be generated by these same known RACE techniques to generate and isolate a portion of the coding region to use as a probe to screen one of numerous types of cDNA and/or genomic libraries in order to isolate a full-length version of the nucleotide sequence encoding rhCEA.

It is readily apparent to those skilled in the art that other types of libraries, as well as libraries constructed from other cell types-or species types, may be useful for isolating a rhCEA-encoding DNA or a rhCEA homologue. Other types of libraries include, but are not limited to, cDNA libraries derived from other cells. The selection of cells or cell lines for use in preparing a cDNA library to isolate a cDNA encoding rhCEA may be done by first measuring cell-associated rhCEA activity using any known assay available for such a purpose.

Preparation of cDNA libraries can be performed by standard techniques well known in the art. Well known cDNA library construction techniques can be found for example, in Sambrook et al., *Molecular Cloning: A Laboratory*

*Manual*; Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, 1989. Complementary DNA libraries may also be obtained from numerous commercial sources, including but not limited to Clontech Laboratories, Inc. (Palo Alto, CA) and Stratagene (La Jolla, CA).

The DNA molecules, RNA molecules, and recombinant protein of the present invention may be used to screen and measure levels of rhCEA. The recombinant proteins, DNA molecules, and RNA molecules lend themselves to the formulation of kits suitable for the detection and typing of rhCEA. Such a kit would comprise a compartmentalized carrier suitable to hold in close confinement at least one container. The carrier would further comprise reagents such as recombinant rhCEA or anti-rhCEA antibodies suitable for detecting rhCEA. The carrier may also contain a means for detection such as labeled antigen or enzyme substrates or the like.

All publications mentioned herein are incorporated by reference for the purpose of describing and disclosing methodologies and materials that might be used in connection with the present invention. Nothing herein is to be construed as an admission that the invention is not entitled to antedate such disclosure by virtue of prior invention.

Having described preferred embodiments of the invention with reference to the accompanying drawings, it is to be understood that the invention is not limited to those precise embodiments, and that various changes and modifications may be effected therein by one skilled in the art without departing from the scope or spirit of the invention as defined in the appended claims.

The following examples illustrate, but do not limit the invention.

### EXAMPLE 1

#### Isolation of RNA from Rhesus Macaques

Molecular procedures were performed following standard procedures well known in the art (*See, e.g.,* Ausubel et. al. *Short Protocols in Molecular Biology*, F.M., -2nd. ed., John Wiley & Sons, (1992) and Sambrook et al., *Molecular Cloning, A Laboratory Manual*, 2nd ed., Cold Spring Harbor Laboratory Press (1989), which are hereby incorporated by reference).

To obtain RNA for the isolation of the rhesus CEA cDNA, colon samples from two different Rhesus monkeys (*Macaca Mulatta*) were used. Frozen tissues were obtained from The Biomedical Primate Research Center (BPRC, Rijswijk, the Netherlands). To extract total RNA from rhesus colon samples, tissues were mechanically pulverized and combined with the Ultraspec RNA reagent (Biotecx Laboratories; Houston, TX) according to the manufacturer's instructions. The integrity of the purified RNA was verified by formaldehyde-denaturing agarose gel. Samples were aliquoted and stored at -80°C.

## EXAMPLE 2

### Rhesus CEA cDNA Amplification

Nucleotide sequences from the 5' and 3' untranslated regions (UTR) of all known members of the human CEA family were aligned to identify highly conserved regions of the CEA DNA (see FIGURE 3). Based on the CEA gene family homologies identified, degenerate oligonucleotide primers were designed and PCR conditions were optimized to amplify the rhesus CEA cDNA by reverse transcriptase polymerase chain reaction (RT-PCR), described below. The primers used to amplify the entire cDNA were as follows: 5'-RhCEA EcoRI 5'- C C G A A T T C C G G A C A S A G C A G R C A G C A G R S A C C -3' (SEQ ID NO:3) and CEA-8 RhXhoI 5'- C C G C T C G A G C G G C T G C T A C A T C A G A G C A A C C C C A A C C -3' (SEQ ID NO:4). The amplification was performed with the SuperScript One-Step RT-PCR with Platinum Taq kit (Invitrogen; Carlsbad, CA). A 100 µl reaction volume was used which consisted of 1 µg of RNA, 200pmol of both primers, and 10% DMSO (final concentration).

To perform the reverse transcription step, total RNA samples isolated from each of the two rhesus monkeys were incubated at 45°C for 30 min, followed by a 2 minute incubation at 94°C. PCR amplification of the resulting templates consisted of 40 cycles of 94°C for 15s, 52°C for 30s and 68°C for 2 min and 20s.

Amplified PCR products of about 2100 bp, the expected size for a CEACAM-5 homolog, were independently obtained from both RNA samples and were purified from agarose gel. Partial sequence analysis of both PCR products revealed high homology with human CEACAM-5.

Due to the high homology of internal repetitions, the entire gene sequence was obtained by purifying DNA fragments using the restriction sites indicated in FIGURE 5. The rhesus CEA nucleotide sequences obtained from each monkey are disclosed herein in FIGURE 1, as set forth in SEQ ID NO:1 (hereinafter rhCEACAM-5) and SEQ ID NO:5 (hereinafter rhCEACAM-5 #2). Analysis of the CEA nucleotide sequences revealed an open reading frame (ORF) of 2118 nucleotides, which encode a 705 amino acid polypeptide. Comparison of the rhCEA nucleotide sequences obtained from two rhesus monkeys indicated that there were two nucleotide differences (see FIGURES 1A and 1B), which code for two different proteins (see FIGURES 2A and 2B).

The rhesus CEACAM-5 nucleotide sequence (SEQ ID NO:1) was also compared to the published human CEACAM-5 sequence (SEQ ID NO:6), which revealed 88% homology at the nucleotide level (see FIGURE 6). A similar comparison of the rhesus (SEQ ID NO:2) and human (SEQ ID NO:7) CEA polypeptide sequences showed 78.9% identity at the amino acid level (see FIGURE 7). Interestingly, a three amino acid insertion is present in the carboxyl-terminus of rhesus CEA compared to human CEA, probably involving the signal for glycosylphosphatidylinositol (GPI) modification.

### EXAMPLE 3

#### Generation and Screening of a Lambda Rhesus CEA-Specific Library.

Amplified rhCEA products obtained by RT-PCR (see EXAMPLE 2) were digested with *EcoRI/XhoI* and ligated into the Lambda ZAP-CMV XR vector (Stratagene; La Jolla, CA), according to manufacturer's directions. The ligation products were incubated with Gigapack III gold packaging extract and the resulting phages were used to infect XL-1 Blue MRF' cells. This CEA-specific primary library was then amplified, obtaining a titer of  $\sim 1 \times 10^6$  pfu/ml. Screening of  $\sim 5 \times 10^3$  plaques was performed by lifting onto nylon filters. Filters were hybridized with two different DNA probes covering the 5' and the 3' ends of the CEA molecule. Double positive plaques were excised in XL-1 Blue MRF' cells and the derived filamentous phages were amplified in XL-OLR cells. The phagemids were then grown and analyzed by restriction digestion. Sequence analysis and Genbank comparisons revealed the highest homology with human CEACAM-5.

## EXAMPLE 4

Plasmid Constructs and Adenovirus Generation

RhCEA was excised with *PstI/XhoI* from pCMV-script EX phagemid vector and inserted in pBluescript II KS vector, obtaining pBS-RhCEA. The insert was entirely sequenced and then subcloned as *SmaI/XhoI* fragment in pVIJnsA vector, obtaining pVIJ-RhCEA. The shuttle plasmid pMRK-RhCEA for adenovirus generation was obtained by subcloning the same fragment in the polyMRK vector. A *PacI/StuI* fragment from pMRK-RhCEA containing the expression cassette for RhCEA and E1 flanking Ad5 regions was recombined to *ClaI* linearized pAd5 or pAd6 in BJ5183 *E. Coli* cells. The resulting plasmids were pAd5-RhCEA and pAd6-RhCEA. Both plasmids were cut with *PacI* to release the adenovirus ITRs and transfected in PerC-6 cells. Viral amplification was carried out through serial passages. Ad5-RhCEA and Ad6-RhCEA were purified using a standard CsCl purification protocol and extensively dialyzed against A105 buffer (5mM Tris pH 8.0, 1mM MgCl<sub>2</sub>, 75mM NaCl, 5% sucrose, 0.005% Tween20).

## EXAMPLE 5

RhCEA Expression and Detection *in vitro*

Expression of RhCEA by the generated vectors was verified by western blot and FACS analysis. Plasmids were transfected in HeLa or PerC.6 cells with Lipofectamine 2000 (Life Technologies; Carlsbad, CA). Adenovirus infections were performed in serum-free medium for 30 min at 37°C, then fresh medium was added. After 48hr of incubation, whole cell lysates were analyzed by western blot using a rabbit polyclonal serum against human CEA (Fitzgerald, 1:1500 dilution). All of the selected rhesus CEA clones expressed a 180-200 KDa protein when transfected in HeLa cells (see FIGURE 4).

For FACS analysis, cells were detached with trypsin and resuspended in FACS buffer (PBS, 1% FCS). After incubation for 30 min with rabbit polyclonal anti-CEA antibody diluted 1:250, cells were washed and incubated for 30 min with an

anti-rabbit IgG-PE and finally analyzed with a FACScalibur (Becton Dickinson, San Jose, CA).

## EXAMPLE 6

### Peptides

In order to analyze the cell mediated immune response against rhesus CEA in immunized animals, 15mer peptides overlapping by 11 amino acids were designed to cover the entire protein. Liophilized rhesus CEA peptides were purchased by Bio-Synthesis, Inc. (Lewisville, TX) and resuspended in DMSO at 40mg/ml. Peptides were grouped into 4 pools: pool A (from RhCEA-1 to RhCEA-34, 34 peptides); pool B (from RhCEA-35 to RhCEA-79, 45 peptides); pool C (from RhCEA-80 to RhCEA-124, 48 peptides); and pool D (from RhCEA-125 to RhCEA-173, 53 peptides). Final concentrations were the following: pool A=1.176mg/ml; pool B=0.888mg/ml; pool C=0.851mg/ml; pool D=0.769mg/ml. Peptides and pools were stored at -80°C.

## EXAMPLE 7

### Generation of CEA-specific cellular immune responses in mice by immunization with rhCEA

CEA.Tg mice are transgenic mice that express human CEA as a self-antigen with a tissue distribution similar to that of humans. As largely demonstrated in the scientific literature, these mice are unresponsive to CEA, as shown by the lack of detectable CEA-specific serum antibodies and the inability to prime an *in vitro* splenic T-cell response to CEA. Many reports have shown that DNA immunization with xenogeneic genes encoding homologous antigens protects mice against tumor challenge with syngeneic melanoma cells. To demonstrate the capability of xenogeneic DNA vaccination to elicit an immune response against a self-antigen in this model, we immunized CEA.Tg mice with vectors encoding rhesus CEA (xeno).



C57BL/6 mice (H-2<sup>b</sup>) were purchased from Charles River (Lecco, Italy). CEA.tg mice (H-2<sup>b</sup>) were provided by HL Kaufman (Albert Einstein College of Medicine, New York) and kept in standard conditions.

For electro gene transfer (EGT), mice quadriceps were either surgically exposed or directly injected with 50  $\mu$ g pVII-RhCEA and electrically stimulated as previously described (Rizzuto et al. *Proc. Natl. Acad. Sci. U.S.A.* 96(11): 6417-22 (1999)). For adenovirus injection,  $1 \times 10^{10}$  vp of Ad5-RhCEA were injected in mice quadriceps.

Mice were injected in the quadriceps muscle with 50  $\mu$ g pVII-RhCEA and electrostimulated immediately after injection once a week for 4 weeks. C57BL/6 mice were used as controls. Antibodies against rhesus CEA were detected in sera from these mice by western blot, demonstrating a humoral immune response. A mouse monoclonal Ab against hCEA was used as positive control, while pre-immune sera and mock-infected cell extracts were used as negative controls (data not shown). Importantly, cross-reactive antibodies against human CEA protein could be measured only in rhesus CEA immunized groups (FIGURE 8) with an average titer of 1:110. These data indicate that, in the transgenic mouse model, it is possible to break tolerance with xenogeneic DNA vaccination (measured as anti-CEA autoantibodies).

## EXAMPLE 8

### Antibody Detection and Titration

Sera for antibody titration were obtained by retro-orbital bleeding. For western blot detection, extracts from HeLa cells transduced with Ad5-rhCEA were run on SDS-page gels and transferred onto nitrocellulose filters. Sera were pooled and diluted 1:50 for O/N incubation at 4°C. An anti-mouse IgG-AP conj. (Sigma, 1:2500) was used for the detection. For titration, Elisa plates (Nunc maxisorp) were coated with 100ng/well CEA (highly pure CEA; Fitzgerald Industries International Inc., Concord MA), diluted in coating buffer (50mM NaHCO<sub>3</sub> pH 9.4) and incubated O/N at 4°C. Plates were then blocked with PBS containing 5% BSA for 1 hr at 37°C. Mouse sera were diluted in PBS 5% BSA (dilution 1/50 to evaluate seroconversion rate; dilutions from 1:10 to 1:31,250 to evaluate titre value). Pre-immune sera were used as background. Diluted sera were incubated O/N at 4°C. Washes were carried out with PBS, 1%BSA, 0.05% tween 20. Detecting antibody (goat anti-mouse IgG

Peroxidase, Sigma, St. Louis, MO) was diluted 1/2000 in PBS, 5%BSA.) and incubated for 2-3 hr at room temp. on a shaker. After washing, plates were developed with 100 $\mu$ l/well of TMB substrate (Pierce Biotechnology, Inc., Rockford, IL). Reactions were stopped with 25 $\mu$ l/well of 1M H<sub>2</sub>SO<sub>4</sub> solution and plates were read at 450 nm/620 nm. Anti-CEA serum titers were calculated as the limiting dilution of serum producing an absorbance at least 3-fold greater than the absorbance of autologous pre-immune serum at the same dilution.

## EXAMPLE 9

### IFN- $\gamma$ ELISPOT Assay

96-well MAIP plates (Millipore, Bedford, MA) were coated with purified rat anti-mouse IFN- $\gamma$  (IgG1, clone R4-6A2, Pharmingen, San Diego, CA) at 2.5 $\mu$ g/ml in sterile PBS, aliquoted at 100 $\mu$ l per well. After washing with sterile PBS, plates were blocked with 200 $\mu$ l per well of R10 medium at 37 °C for at least 2 hours.

For splenocyte preparation, the spleen was removed from a sacrificed mouse in a sterile manner and disrupted by scratching through a grid. Osmotic lysis of red blood cells was obtained by adding 1 ml of 0.1X PBS to the cell pellet and vortexing for no more than 15 sec. 1 ml of 2X PBS was then added and the volume was brought up to 4ml with PBS 1X. After spinning at 1200 rpm for 10 minutes at room temp., the cell pellet was resuspended in 1 ml of R10 medium and viable cells were counted. Splenocytes were plated at 5x10<sup>5</sup> and 2x10<sup>5</sup>/well with 1 $\mu$ g/ml each peptide in R10 and incubated for 20h in a CO<sub>2</sub> incubator at 37°C. Concanavalin A (ConA) at 5 $\mu$ g/ml was used as a positive internal control for each mouse. After washing with PBS, 0.05% Tween 20, plates were incubated O/N at 4°C with 50 $\mu$ l/well of biotin-conjugated rat anti-mouse IFN- $\gamma$  (Rat IgG1, clone XMG 1.2, Pharmingen, San Jose, CA) diluted 1:250 in assay buffer (PBS-5%FBS - 0.005% Tween-20).

The next day, plates were washed and incubated for 2h at room temp. with Streptavidin-AP conjugate (Pharmingen) diluted 1:2500 in assay buffer. After extensive washing, plates were developed by addition of 50 $\mu$ l/well NBT/B-CIP (Pierce Biotechnology) until development of spots was observed under the microscope. The reaction was stopped by washing plates thoroughly with distilled

water. Plates were allowed to air-dry completely, and spots were counted using an automated ELISPOT reader.

For cell mediated immune response, CEA.Tg mice were vaccinated either with hCEA expressing vectors or with rhCEA expressing vectors. Two groups were analyzed: the first group was analyzed by ELISPOT assay 21 days after last DNA injection, while the second group was boosted with  $1 \times 10^{10}$  vp of either Ad5-hCEA or Ad5-RhCEA and analyzed two weeks later. Results demonstrated that after four DNA injections, no significant cellular immune-response against hCEA was observed as measured by ELISPOT (not shown). On the other hand, mice that were boosted with Ad5 demonstrated a considerably increased response, consistent with breaking the immune-tolerance to CEA. This observation suggests that a useful vaccination protocol for the CEA self antigen would be the repeated administration of DNA by EGT, followed by an adenovirus boost (mixed modality). Importantly, immunization with rhesus CEA provided cross-reaction with human CEA peptides and vice-versa both in wild type and transgenic mice (data not shown). In particular, the immune response against human CEA was much better in transgenic mice using rhCEA as the immunogen (see FIGURE 9). These results show that a good response against CEA in transgenic mice could be obtained using the rhesus (xeno) gene. Response against rhesus CEA peptides is shown in FIGURE 10.

## EXAMPLE 10

### Immunization of Rhesus Macaques with rhCEA

In order to assess the efficiency of immunization of rhesus macaques (*macaca mulatta*) with the rhesus homologue of the human tumour antigen CEA, which is expressed in colorectal carcinomas, immunization studies were performed at the Biomedical Primate Research Centre (BPRC, Rijswijk, The Netherlands). Such immunization studies were designed to evaluate both B and T cell responses to immunization with the rhesus CEA antigen.

In this study (CV-1), 1 group of monkeys (consisting of 2 males and 2 females) was immunized with a plasmid DNA vector and adenovirus vector expressing rhesus CEACAM-5. For priming, animals were vaccinated intramuscularly with plasmid DNA expressing rhCEA at weeks 0, 4, 8, 12, and 16 by injection of DNA followed by electrical stimulation. The DNA injection consisted of

a 1 ml solution (split over 2 sites with 0.5 ml/site) containing 5 mg plasmid DNA for animals weighing 2-5 kilos. Animals were injected under anesthesia (mixture of ketamine/xylazine).

For electrostimulation, 2 trains of 100 square bipolar pulses (1 sec each), were delivered every other second for a total treatment time of 3 sec. The pulse length was 2 msec/phase with a pulse frequency and amplitude of 100 Hz and 100 mA (constant current mode), respectively.

To measure the immune response to CEA using the above immunization protocol, blood samples were collected every four weeks. The cell mediated response was measured by IFN $\gamma$  Elispot assay and the humoral response was measured by ELISA assay. Because no significant immune response was obtained at week 16, two further injections (week 24 and 28) were carried out using Ad5 expressing rhCEA. Upon Ad5 injection, a measurable immune response against rhCEA was detected for two monkeys (RI137 and CO12) covering peptide pool C and pool B + C, respectively. The cell mediated immune response began to decline in both monkeys at week 35.

The humoral immune response was followed over time upon DNA injection. Three monkeys (CO12, RI311 and RI002) showed a good anti-CEA antibody titer, ranging from 1:143 to 1:2099 and reaching a peak between weeks 12 and 16 after the first injection.

These data show that genetic vectors encoding rhCEA were able to break the immune tolerance to this tumor antigen in primates. Both cell mediated (50% of treated monkeys) and humoral (75% of treated monkeys) immunity were involved in the immune response.

## EXAMPLE 11

### Immunization of Rhesus Macaques with Rhesus Homologs of Human Tumor-Associated Antigens

A second series of immunization studies was performed in order to assess the efficiency of immunization of Rhesus macaques (*Macaca mulatta*) with rhesus homologues of the human tumor antigens HER2/neu, Ep-CAM and CEA, which are all expressed in colorectal carcinomas. Protocols were designed to evaluate both B and T cell responses to these tumor antigens in combination.

In this study, a second group of 4 rhesus monkeys (2 males and 2 females) were immunized with a mixture of three plasmid DNA vectors expressing the rhesus homologues of human tumor antigens Ep-CAM (pV1J-rhEpCAM), CEA pV1J-rhCEA), and HER2/neu (pV1J-rhHER2).

Animals were primed by intramuscular injection of plasmid DNA at weeks 0, 4, 8, 12, and 16, followed by electrostimulation. The DNA injection consisted of a 1 ml solution (split over 2 sites with 0.5 ml/site) containing 6 mg plasmid DNA for animals weighing 2-5 kilos. Animals were injected under anesthesia (mixture of ketamine/xylazine).

For electrostimulation, 2 trains of 100 square bipolar pulses (1 sec each), were delivered every other second for a total treatment time of 3 sec. The pulse length was 2 msec/phase with a pulse frequency and amplitude of 100 Hz and 100 mA (constant current mode), respectively.

The same group of animals was boosted by injection of a mixture of three Ad5-expressing rhesus CEA (Ad5-rhCEA), rhesus HER2/neu (Ad5-rhHER2), and rhesus EpCAM (Ad5-rhEpCAM). A total amount of  $3 \times 10^{11}$  viral particles (vp), were injected i.m. at weeks 23 and 27 ( $1 \times 10^{11}$  vp for each of the three viruses).

To measure the immune response to the three tumor antigens using the above immunization protocol, blood samples were collected every four weeks. The cell mediated immune response was measured by IFN- $\gamma$  ELISPOT assay, whereas the humoral response was measured by ELISA.

Monkeys RI449 and RI519 showed a detectable HER2-specific cell-mediated response, as measured by IFN- $\gamma$  ELISPOT analysis. A similar analysis did not detect any significant response against rhCEA and rhEpCAM.

In a third study, 4 rhesus monkeys were immunized with a mixture of Ad5-rhHER2, Ad5-rhCEA and Ad5-rhEpCAM by i.m. injection of Ad5 derivatives at weeks 0, 2 and 4. A 1 ml solution (split over 2 sites with 0.5 ml/site) containing  $3 \times 10^{11}$  vp ( $10^{11}$  for each of the three Ad5 virus) was administered to animals weighing 2-5 kilos, under anesthesia (mixture of ketamine/xylazine).

The cell mediated response was measured by IFN $\gamma$  ELISPOT assay. For Her2/Neu, three out of four monkeys showed a detectable response. No significant cell mediated responses were measured for rhCEA and rhEpCAM.

In summary, the immunization protocol discussed above was effective in inducing a specific immune response against rhHER2/neu in rhesus monkeys. It is

unclear why co-immunization with vectors carrying three different tumour antigens was not effective in inducing an immune response against rhCEA, as compared to study 1, which used only rhCEA as immunogen. Though not wishing to be bound by theory, it is possible that the expression of rhHER2/Neu and the presence of immunodominant epitopes limited the generation and the expansion of subdominant rhCEA specific T-cells.

## WHAT IS CLAIMED IS:

1. An isolated nucleic acid molecule, comprising a sequence of nucleotides that encodes a rhesus monkey carcinoembryonic antigen (rhCEA) protein as set forth in SEQ ID NO:2.
2. The isolated nucleic acid molecule of claim 1 wherein the nucleic acid is DNA.
3. The isolated nucleic acid molecule of claim 1 wherein the nucleic acid is mRNA.
4. The isolated nucleic acid molecule of claim 1 wherein the nucleic acid is cDNA.
5. The isolated nucleic acid molecule of claim 1 wherein the sequence of nucleotides comprises the sequence of nucleotides set forth in SEQ ID NO:1.
6. A vector comprising the nucleic acid molecule of claim 1.
7. A host cell comprising the vector of claim 6.
8. A process for expressing a rhesus carcinoembryonic antigen (CEA) protein in a recombinant host cell, comprising:
  - (a) introducing a vector comprising the nucleic acid of claim 1 into a suitable host cell; and,
  - (b) culturing the host cell under conditions which allow expression of said rhesus CEA protein.
9. A process for expressing a rhesus carcinoembryonic antigen (CEA) protein in a recombinant host cell, comprising:
  - (a) introducing a vector comprising the nucleic acid of claim 5 into a suitable host cell; and,

(b) culturing the host cell under conditions which allow expression of said rhesus CEA protein.

10. An isolated and purified rhesus CEA polypeptide comprising a sequence of amino acids as set forth in SEQ ID NO:2.

11. An isolated nucleic acid molecule, comprising a sequence of nucleotides that encodes a rhesus monkey carcinoembryonic antigen (rhCEA) protein as set forth in SEQ ID NO:18.

12. The isolated nucleic acid molecule of claim 11 wherein the nucleic acid is DNA.

13. The isolated nucleic acid molecule of claim 11 wherein the nucleic acid is mRNA.

14. The isolated nucleic acid molecule of claim 11 wherein the nucleic acid is cDNA.

15. The isolated nucleic acid molecule of claim 11 wherein the sequence of nucleotides comprises the sequence of nucleotides set forth in SEQ ID NO:5.

16. A vector comprising the nucleic acid molecule of claim 11.

17. A host cell comprising the vector of claim 16.

18. A process for expressing a rhesus carcinoembryonic antigen (CEA) protein in a recombinant host cell, comprising:

(a) introducing a vector comprising the nucleic acid of claim 11 into a suitable host cell; and,

(b) culturing the host cell under conditions which allow expression of said rhesus CEA protein.



19. An isolated and purified rhesus CEA polypeptide comprising a sequence of amino acids as set forth in SEQ ID NO:18.

20. A method of preventing or treating cancer comprising administering to a mammal a vaccine vector comprising an isolated nucleic acid molecule, the isolated nucleic acid molecule comprising a sequence of nucleotides that encodes a rhesus monkey carcinoembryonic antigen (rhCEA) protein as set forth in SEQ ID NO:2 or SEQ ID NO:18.

21. A method according to claim 20 wherein the mammal is human.

22. A method according to claim 20 wherein the vector is an adenovirus vector or a plasmid vector.

23. A method according to claim 20 wherein the vector is an adenoviral vector comprising an adenoviral genome with a deletion in the adenovirus E1 region, and an insert in the adenovirus E1 region, wherein the insert comprises an expression cassette comprising:

- (a) a polynucleotide encoding a rhesus monkey CEA protein; and
- (b) a promoter operably linked to the polynucleotide.

24. A method according to claim 20 wherein the vector is a plasmid vaccine vector, which comprises a plasmid portion and an expressible cassette comprising

- (a) a polynucleotide encoding a rhesus monkey CEA protein; and
- (b) a promoter operably linked to the polynucleotide.

25. An adenovirus vaccine vector comprising an adenoviral genome with a deletion in the E1 region, and an insert in the E1 region, wherein the insert comprises an expression cassette comprising:

- (a) a polynucleotide encoding a rhesus monkey CEA protein; and
- (b) a promoter operably linked to the polynucleotide.

26. An adenovirus vector according to claim 25 which is an Ad 5 vector.
27. An adenovirus vector according to claim 25 which is an Ad 6 vector.
28. A vaccine plasmid comprising a plasmid portion and an expression cassette portion, the expression cassette portion comprising:
- (a) a polynucleotide encoding a rhesus monkey CEA protein; and
  - (b) a promoter operably linked to the polynucleotide.
29. A method of protecting a mammal from cancer comprising:
- (a) introducing into the mammal a first vector comprising:
    - (i) a polynucleotide encoding a rhesus monkey CEA protein; and
    - (ii) a promoter operably linked to the polynucleotide;
  - (b) allowing a predetermined amount of time to pass; and
  - (c) introducing into the mammal a second vector comprising:
    - (i) a polynucleotide encoding a rhesus monkey CEA protein; and
    - (ii) a promoter operably linked to the polynucleotide.
30. A method according to claim 29 wherein the first vector is a plasmid and the second vector is an adenovirus vector.
31. A method according to claim 29 wherein the first vector is an adenovirus vector and the second vector is a plasmid.
32. A method of treating a mammal suffering from a colorectal carcinoma comprising:
- (a) introducing into the mammal a first vector comprising:
    - (i) a polynucleotide encoding a rhesus monkey CEA protein; and
    - (ii) a promoter operably linked to the polynucleotide;
  - (b) allowing a predetermined amount of time to pass; and

- (c) introducing into the mammal a second vector comprising:
  - (i) a polynucleotide encoding a rhesus monkey CEA protein; and
  - (ii) a promoter operably linked to the polynucleotide.

33. A method according to claim 32 wherein the first vector is a plasmid and the second vector is an adenovirus vector.

34. A method according to claim 32 wherein the first vector is an adenovirus vector and the second vector is a plasmid.

1/13

## Nucleotide Sequence of First Rhesus CEA

```

1  ATGGGGTCTC CCTCAGCCCC TCTTCACAGA TGGTGCATCC CCTGGCAGAC
51  GCTCCTGCTC ACAGCCTCAC TTCTAACCTT CTGGAACCCG CCCACCACTG
101 CCCAGCTCAC TATTGAATCC AGGCCGTTCA ATGTTGCAGA GGGGAAGGAG
151 GTTCTTCTAC TTGCCACAA TGTGTCCCAG AATCTTTTGT GCTACATTTG
201 GTACAAGGGA GAAAGAGTGG ATGCCAGCCG TCGAATTGGA TCATGTGTAA
251 TAAGAACTCA ACAAATTACC CCAGGGCCCG CACACAGCGG TCGAGAGACA
301 ATAGACTTCA ATGCATCCCT GCTGATCCAC AATGTCACCC AGAGTGACAC
351 AGGATCCTAC ACCATACAAG TCATAAAGGA AGATCTTGTG AATGAAGAAG
401 CAACTGGCCA GTTCCGGGTA TACCCGGAGC TGCCCAAGCC CTACATCTCC
451 AGCAACAAC TCCAACCCGT GGAGGACAAG GATGCTGTGG CCTTAACCTG
501 TGAACCTGAG ACTCAGGACA CAACCTACCT GTGGTGGGTA AACAAATCAGA
551 GCCTCCCGGT CAGTCCCAGG CTGGAGCTGT CCAGTGACAA CAGGACCCTC
601 ACTGTATTCA ATATTCCAAG AAATGACACA ACATCCTACA AATGTGAAAC
651 CCAGAACCCA GTGAGTGTCA GACGCAGCGA CCCAGTCACC CTGAACGTCC
701 TCTATGGCCC GGATGCGCCC ACCATTTCCC CTCTAAACAC ACCTTACAGA
751 GCAGGGGAAA ATCTGAACCT CACCTGCCAC GCAGCCTCTA ACCCAACTGC
801 ACAGTACTTT TGGTTTGTCA ATGGGACGTT CCAGCAATCC ACACAAGAGC
851 TCTTTATACC CAACATCACC GTGAATAATA GCGGATCCTA TATGTGCCAA
901 GCCCATAACT CAGCCACTGG CCTCAATAGG ACCACAGTCA CGGCGATCAC
951 AGTCTACGCG GAGCTGCCCC AGCCCTACAT CACCAGCAAC AACTCCAACC
1001 CCATAGAGGA CAAGGATGCT GTGACCTTAA CCTGTGAACC TGAGACTCAG
1051 GACACAACCT ACCTGTGGTG GGTAAACAAT CAGAGCCTCT CGGTCAGTTC
1101 CAGGCTGGAG CTGTCCAATG ACAACAGGAC CCTCACTGTA TTCAATATTC
1151 CAAGAAACGA CACAACGTTT TACGAATGTG AGACCCAGAA CCCAGTGAGT
1201 GTCAGACGCA GCGACCCAGT CACCCTGAAT GTCCTCTATG GCCCGGATGC
1251 GCCCACCATT TCCCCTCTAA ACACACCTTA CAGAGCAGGG GAAAATCTGA
1301 ACCTCTCCTG CCACGCAGCC TCTAACCCAG CTGCACAGTA CTCTTGTTTT
1351 GTCAATGGGA CGTTCCAGCA ATCCACACAA GAGCTCTTTA TACCCAACAT
1401 CACCGTGAAT AATAGCGGAT CCTATATGTG CCAAGCCCAT AACTCAGCCA
1451 CTGGCCTCAA TAGGACCACA GTCACGGCGA TCACAGTCTA TGTGGAGCTG
1501 CCAAGCCCT ACATCTCCAG CAACAACCTC AACCCCATAG AGGACAAGGA
1551 TGCTGTGACC TTAACCTGTG AACCTGTGGC TGAGAACACA ACCTACCTGT
1601 GGTGGGTAAA CAATCAGAGC CTCTCGGTCA GTCCCAGGCT GCAGCTCTCC
1651 AATGGCAACA GGATCCTCAC TCTACTCAGT GTCACACGGA ATGACACAGG
1701 ACCCTATGAA TGTGGAATCC AGAACTCAGA GAGTGCAAAA CGCAGTGACC
1751 CAGTCACCC TGAATGTCACC TATGGCCCAG ACACCCCAT CATATCCCCC
1801 CCAGACTTGT CTTACCGTTC GGGAGCAAAC CTCAACCTCT CCTGCCACTC
1851 GGA CTCTAAC CCATCCCCGC AGTATTCTTG GCTTATCAAT GGGACACTGC
1901 GGCAACACAC ACAAGTTCTC TTTATCTCCA AAATCACATC AAACAATAGC
1951 GGGGCCTATG CCTGTTTTGT CTCTAACTTG GCTACCGGTC GCAATAACTC
2001 CATAGTCAAG AACATCTCAG TCTCCTCTGG CGATTGAGCA CCTGGAAGTT
2051 CTGGTCTCTC AGCTAGGGCT ACTGTCGGCA TCATAATTGG AATGCTGGTT
2101 GGGGTTGCTC TGATGTAG (SEQ ID NO:1)

```

FIG.1A

2/13

## Nucleotide Sequence of Second Rhesus CEA

```

1  ATGGGGTCTC CCTCAGCCCC TCTTCACAGA TGGTGCATCC CCTGGCAGAC
51  GCTCCTGCTC ACAGCCTCAC TTCTAACCTT CTGGAACCCG CCCACCACTG
101 CCCAGCTCAC TATTGAATCC AGGCCGTTCA ATGTTGCAGA GGGGAAGGAG
151 GTTCTTCTAC TTGCCCACAA TGTGTCCCAG AATCTTTTGG GCTACATTTG
201 GTACAAGGGA GAAAGAGTGG ATGCCAGCCG TCGAATTGGA TCATGTGTAA
251 TAAGAACTCA ACAAATTACC CCAGGGCCCG CACACAGCGG TCGAGAGACA
301 ATAGACTTCA ATGCATCCCT GCTGATCCAC AATGTCACCC AGAGTGACAC
351 AGGATCCTAC ACCATACAAG TCATAAAGGA AGATCTTGTG AATGAAGAAG
401 CAACTGGCCA GTTCCGGGTA TACCCGGAGC TGCCCAAGCC CTACATCTCC
451 AGCAACAAC TCAACCCCGT GGAGGACAAG GATGCTGTGG CCTTAACCTG
501 TGAACCTGAG ACTCAGGACA CAACCTACCT GTGGTGGGTA AACAATCAGA
551 GCCTCCCGGT CAGTCCCAGG CTGGAGCTGT CCAGTGACAA CAGGACCCTC
601 ACTGTATTCA ATATTCCAAG AAATGACACA ACATCCTACA AATGTGAAAC
651 CCAGAACCCA GTGAGTGTCA GACGCAGCGA CCCAGTCACC CTGAACGTCC
701 TCTATGGCCC GGATGCGCCC ACCATTTCCC CTCTAAACAC ACCTTACAGA
751 GCAGGGGAAA ATCTGAACCT CACCTGCCAC GCAGCCTCTA ACCCAACTGC
801 ACAGTACTTT TGGTTTGTCA ATGGGACGTT CCAGCAATCC ACACAAGAGC
851 TCTTTATACC CAACATCACC GTGAATAATA GCGGATCCTA TATGTGCCAA
901 GCCCATAACT CAGCCACTGG CCTCAATAGG ACCACAGTCA CGGCGATCAC
951 AGTCTACGCG GAGCTGCCCC AGCCCTACAT CACCAGCAAC AACTCCAACC
1001 CCATAGAGGA CAAGGATGCT GTGACCTTAA CCTGTGAACC TGAGACTCAG
1051 GACACAACCT ACCTGTGGTG GGTAAACAAT CAGAGCCTCT CGGTCAAGTT
1101 CAGGCTGGAG CTGTCCAATG ACAACAGGAC CCTCACTGTA TTCAATATTC
1151 CAAGAAACGA CACAACGTTT TACGAATGTG AGACCCAGAA CCCAGTGAGT
1201 GTCAGACGCA GCGACCCAGT CACCCTGAAT GTCCTCTATG GCGCGGATGC
1251 GCCCACCATT TCCCCTCTAA ACACACCTTA CAGAGCAGGG GAAAATCTGA
1301 ACCTCTCCTG CCACGCAGCC TCTAACCCAG CTGCACAGTA CTTTTGGTTT
1351 GTCAATGGGA CGTTCAGCA ATCCACACAA GAGCTCTTTA TACCAACAT
1401 CACCGTGAAT AATAGCGGAT CCTATATGTG CCAAGCCCAT AACTCAGCCA
1451 CTGGCCTCAA TAGGACCACA GTCACGGCGA TCACAGTCTA TGTGGAGCTG
1501 CCCAAGCCCT ACATCTCCAG CAACAACCTC AACCCTATAG AGGACAAGGA
1551 TGCTGTGACC TTAACCTGTG AACCTGTGGC TGAGAACACA ACCTACCTGT
1601 GGTGGGTAAA CAATCAGAGC CTCTCGGTCA GTCCCAGGCT GCAGCTCTCC
1651 AATGGCAACA GGATCCTCAC TCTACTCAGT GTCACACGGA ATGACACAGG
1701 ACCCTATGAA TGTGGAATCC AGAACTCAGA GAGTGCAAAA CGCAGTGACC
1751 CAGTCACCC TGAATGTCACC TATGGCCCAG ACACCCCAT CATATCCCCC
1801 CCAGACTTGT CTTACCGTTC GGGAGCAAAC CTCAACCTCT CCTGCCACTC
1851 GGACTCTAAC CCATCCCCGC AGTATTCTTG GCTTATCAAT GGGACACTGC
1901 GGCAACACAC ACAAGTTCTC TTTATCTCCA AAATCACATC AAACAATAAC
1951 GGGGCCTATG CCTGTTTTGT CTCTAACTTG GCTACCGGTC GCAATAACTC
2001 CATAGTCAAG AACATCTCAG TCTCCTCTGG CGATTACGCA CCTGGAAGTT
2051 CTGGTCTCTC AGCTAGGGCT ACTGTCGGCA TCATAATTGG AATGCTGGTT
2101 GGGGTTGCTC TGATGTAG (SEQ ID NO:5)

```

FIG.1B

## 3/13

## Predicted Amino Acid Sequence of First Rhesus CEA Protein

```

1  MGSPSAPLHR WCIPWQTL L TASLLTFWNP PTTAQLTIES RPFNVAEGKE
51  VLLLAHNVSQ NLFGYIWYKG ERVDASRRIG SCVIRTQQIT PGPAHSGRET
101 IDFNASLLIH NVTQSDTGSY TIQVIKEDLV NEEATGQFRV YPELKPYPIS
151 SNNSNPVEDK DAVALTCEPE TQDTTYLWWV NNQSLPVSPR LELSSDNRTL
201 TVFNIPRNDT TSYKCETQNP VSVRRSDPVT LNVLYGPDAP TISPLNTPYR
251 AGENLNLTCH AASNPTAQYF WFNVTGTFQQS TQELFIPNIT VNNSGSYMCO
301 AHNSATGLNR TTVTAITVYA ELPKPYITSN NSNPIEDKDA VTLTCEPETQ
351 DTTYLWWVNN QSLSVSSRLE LSNDNRTLTV FNIPRNDTTF YECETQNPVS
401 VRRSDPVTLN VLYGPDAPTI SPLNTPYRAG ENLNLSCHAA SNPAAQYSWF
451 VNGTFQOSTQ ELFIPNITVN NSGSYMCOAH NSATGLNRTT VTAITVYVEL
501 PKPYISSNNS NPIEDKDAVT LTCEPVAENT TYLWWVNNQS LSVSPRLQLS
551 NGRILTL LLS VTRNDTG PYE CGIQNS EAK RSDPVT LNVT YGPDTP IISP
601 PDL SYRSGAN LNL SCHSDSN PSPQYSWLIN GTLRQHTQVL FISKITSNNS
651 GAYACFVSNL ATGRNNSIVK NISVSSGDSA PGSSGLSARA TVGIIIGMLV
701 GVALM (SEQ ID NO:2.)

```

## FIG.2A

## Predicted Amino Acid Sequence of Second Rhesus CEA Protein

```

1  MGSPSAPLHR WCIPWQTL L TASLLTFWNP PTTAQLTIES RPFNVAEGKE
51  VLLLAHNVSQ NLFGYIWYKG ERVDASRRIG SCVIRTQQIT PGPAHSGRET
101 IDFNASLLIH NVTQSDTGSY TIQVIKEDLV NEEATGQFRV YPELKPYPIS
151 SNNSNPVEDK DAVALTCEPE TQDTTYLWWV NNQSLPVSPR LELSSDNRTL
201 TVFNIPRNDT TSYKCETQNP VSVRRSDPVT LNVLYGPDAP TISPLNTPYR
251 AGENLNLTCH AASNPTAQYF WFNVTGTFQQS TQELFIPNIT VNNSGSYMCO
301 AHNSATGLNR TTVTAITVYA ELPKPYITSN NSNPIEDKDA VTLTCEPETQ
351 DTTYLWWVNN QSLSVSSRLE LSNDNRTLTV FNIPRNDTTF YECETQNPVS
401 VRRSDPVTLN VLYGPDAPTI SPLNTPYRAG ENLNLSCHAA SNPAAQYFWF
451 VNGTFQOSTQ ELFIPNITVN NSGSYMCOAH NSATGLNRTT VTAITVYVEL
501 PKPYISSNNS NPIEDKDAVT LTCEPVAENT TYLWWVNNQS LSVSPRLQLS
551 NGRILTL LLS VTRNDTG PYE CGIQNS EAK RSDPVT LNVT YGPDTP IISP
601 PDL SYRSGAN LNL SCHSDSN PSPQYSWLIN GTLRQHTQVL FISKITSNNN
651 GAYACFVSNL ATGRNNSIVK NISVSSGDSA PGSSGLSARA TVGIIIGMLV
701 GVALM (SEQ ID NO:8)

```

## FIG.2B

Alignment of 5' Untranslated Region of Human CEACAM Family Members

	(57)	57	70	80	90	100	110	120	130	141	
HCEACAM5	(56)	AACGTTCCCTGGAACTC	-AAGCTCTCTCTCCAC	CAGAGGAGGACAGAGGACACAG	CAGAGACC	---	ATGGAGTCTCCCTCGGCCCTC				(SEQ ID NO:10)
HCEACAM6	(36)	AGCAITTCCTGGAGCTC	-AAGCTC-TCTACAAAGAGGT	TGCACAGACAGACAGCAG	CAGAGACC	---	ATGGGACCCCCCTCAGCCCCCTC				(SEQ ID NO:11)
HCEACAM1	(14)	AGCGTTCCTGGAGCCC	-AAGTCTCTCTCCAC	CAGGTGAAGAGAGCGCCAC	CAGGAGACACC	---	ATGGGGCACCTCTCAGCCCCAC				(SEQ ID NO:12)
HCEACAM8	(1)	-----	-----	-----	GCACAGAGGAGAACACG	-CAGGCAGCAGAGACC	---	ATGGGGGCGATCTCAGCCCCCTT			(SEQ ID NO:13)
HCEACAM7	(13)	AGAGTTCCTGGAGCGCC	CAAGCTCTCTCTCCACAGAGGA	---	CAAGCAGGCAGCAGAGACC	---	ATGGGTTCCCGTTCAGCCTGTC				(SEQ ID NO:14)
HCEACAM3	(1)	---	TCCTGGAGCCC	-AGGCTCTCTCTCCACAGAGGAGGA	AGAGCAGGCAGCAGAGACC	---	ATGGGGGCCCCCTCAGCCCCCTC				(SEQ ID NO:15)
HCEACAM4	(44)	AGCGTTCCTGGAGCCC	-A-GCTCTCTCTCCACAG	---	CCACAGGCA	CCCCAGCAGAGACC	---	ATGGGCCCCCGCTCAGCCGCTC			(SEQ ID NO:16)
Consensus	(57)	AGCGTTCCTGGAGCCC	AAGCTCTCTCTCCACAGAGGAGGACAGAGCAGGACGAGAGACC				ATGGGGGCCCCCTCAGCCCCCTC				(SEQ ID NO:9)

FIG.3

5/13




FIG.4



6/13

## SCHEMATIC REPRESENTATION OF RHESUS CEA CODING SEQUENCE.




FIG. 5

[illegible]

FIG. 6A

8/13

Human CEACAM-5 (801) ALAGTATCTTGGTTTGGTTCATGAGCAATCCAAAGAGCTCTTTATCCUUAACATCAGTGTGAATAAAGTGGATCCTATATAGTGGTAA  
Rhesus CEACAM-5 (801) ACAGTACTTTTGGTTTGGTTCATGAGCAATCCAAAGAGCTCTTTATACCCAAACATCAGGTGAATAAATAGCGGATCCTATATAGTGGTAA  
(901) 901 910 920 930 940 950 960 970 980 990 1000  
Human CEACAM-5 (901) GCCATAACTCAGACACTGGCCTCAATAGGACCACAGTCAGACGATCAGAGCTATGCAAGGCCACCCAAACCTTCATCACCAGCAACAACCTCCAACC  
Rhesus CEACAM-5 (901) GCCATAACTCAGCCACTGGCCTCAATAGGACCACAGTCAGGGGATCAGAGTCTAGCGGAGCTGCCAAAGCCCTACATCACCAGCAACAACCTCCAACC  
(1001) 1001 1010 1020 1030 1040 1050 1060 1070 1080 1090 1100  
Human CEACAM-5 (1001) CCGTGGAGGATGAGGATGCTGTAGCCTTAACCTGTGAACCTGAGATTCAGAACACAACCTTACCTGTGGTGGTAAATAATCAGAGCCTCCCGGTCACTCC  
Rhesus CEACAM-5 (1001) CCATAGAGGACAAGGATGCTGTAGCCTTAACCTGTGAACCTGAGACTCAGGACACAACCTTACCTGTGGTGGTAAACAATCAGAGCCTCTCGGTCACTTC  
(1101) 1101 1110 1120 1130 1140 1150 1160 1170 1180 1190 1200  
Human CEACAM-5 (1101) CAGGCTGCAGCTGTCCATGACAACAGGACCTCACTCTACTCAGTGTCAAGGAATGATGTAGGACCTATGAGTGTGGATCCAGAACGAATTAAGT  
Rhesus CEACAM-5 (1101) CAGGCTGGAGCTGTCCATGACAACAGGACCTCACTGTATTCAATATTCGAAGAAACGACACAACGTTTCACGAATGTGAGACCCAGAACCCAGTGAAT  
(1201) 1201 1210 1220 1230 1240 1250 1260 1270 1280 1290 1300  
Human CEACAM-5 (1201) GTTGACCAACAGGACCCAGTCACTCTGAATGTCTCTATGCCCCAGACGACCCCAACCATTTCCCCCTCTATACACCTATTACCGTCCAGGGGTGAACCTCA  
Rhesus CEACAM-5 (1201) GTGAGACGACAGGACCCAGTCACTCTGAATGTCTCTATGCCCCAGATGGGCCACCATTTCCCCCTCTAAACACACACCTTACAGAGCAGGGGAAAATCTGA  
(1301) 1301 1310 1320 1330 1340 1350 1360 1370 1380 1390 1400  
Human CEACAM-5 (1301) GCCTCTCCTGCGCATGCGGCTCTAACCCAGCTGCACAGTATCTTGGCTGATGATGGGAACATCCAGGAACACACACAGAGGCTCTTTATCTCCAACAT  
Rhesus CEACAM-5 (1301) ACCTCTCCTGCGCAGCGCTCTAACCCAGCTGCACAGTACTCTTGGTTGTCAATGGGAGCTCCAGCAATCCACACAAGAGCTCTTTATACCCCAACAT  
(1401) 1401 1410 1420 1430 1440 1450 1460 1470 1480 1490 1500  
Human CEACAM-5 (1401) CACTGAGAAGAACAGCGGACTCTATACCTGCGGAGCAATTAACCTCAGCAGTGGCCACAGCAGGACTACAGTCAAGACAATCAGAGTCTCTGCGGAGCTG  
Rhesus CEACAM-5 (1401) CACCGTGAATTAATAGCGGATCTATATGTGCGGAGCAATTAACCTCAGCCACTGGCCTCAATAGGACCACAGTCAAGGCGATCAGAGTCTATGTGGAGCTG  
(1501) 1501 1510 1520 1530 1540 1550 1560 1570 1580 1590 1600  
Human CEACAM-5 (1501) CCCAAGCCCTCCATCTCCAGCAACAACCTCCAAACCCGTGGAGGACAAGGATGCTGTGGCTTCACCTGTGGAACCTGAGGCTCAGAACACAAACCTACCTGT  
Rhesus CEACAM-5 (1501) CCCAAGCCCTACATCTCCAGCAACAACCTCCAAACCCCATAGAGGACAAGGATGCTGTGACCTTAACCTGTGGAACCTGTGGCTGAGAACACAAACCTACCTGT

FIG. 6B

9/13

```

Rhesus CEACAM-5 (1601) GGTGGGTAAACAATCAGAGCCTCTGGGTCAAGTCCAGGGCTGCAGCTCTCCAAATGGCAACAGGATCCTCACTCTACTCAGTGTACACAGGAAATGACACAGG
(1701) 1701 1710 1720 1730 1740 1750 1760 1770 1780 1790 1800
Human CEACAM-5 (1701) AGCCTATGATGTGGAAATCCAGAACTCAGTGAAGTGCAAAACCGCAGTGACCAAGTCACCCCTGGATGTTCTCTATGGGCCGACACCCCCCATCATTTCCCCC
Rhesus CEACAM-5 (1701) ACCCTATGAATGTGGAAATCCAGAACTCAGAGAGTGCAAAACCGCAGTGACCCAGTCACCCCTGAATGTCACCTATGGCCCCAGACACCCCCCATCATATATCCCCC
(1801) 1801 1810 1820 1830 1840 1850 1860 1870 1880 1890 1900
Human CEACAM-5 (1801) CCAGACTGGTCTTACCTTTGGGAGCGAACCTCAACCTCTCTGCCACTCGGCTCTAACCCATCCCCCGCAGTATCTTGGCGTATCAATGGGATACCGC
Rhesus CEACAM-5 (1801) CCAGACTTGTCTTACCGTTGGGAGCGAAACCTCAACCTCTCTGCCACTCGGCTCTAACCCATCCCCCGCAGTATCTTGGCTTATCAATGGGACACTGC
(1901) 1901 1910 1920 1930 1940 1950 1960 1970 1980 1990 2000
Human CEACAM-5 (1901) AGCAACACACACAAGTCTCTTTATGCGCAAAATCACGCCAAATAATAACGGGACCTATGCTGTTTGTCTCTAACTTGGCTACTGGCCGCAATAATTC
Rhesus CEACAM-5 (1901) GGCACACACACAAGTCTCTTTATCTCCAAATCACATCAACAATAGCGGGGCTATGCTGTTTGTCTCTAACTTGGCTACCGTCCGCAATAACTC
(2001) 2001 2010 2020 2030 2040 2050 2060 2070 2080 2090 2100
Human CEACAM-5 (2001) CATAGTCAAGAGCATCACAGTCTCT-----GCATCTGGAACTTCTCTGGTCTCTCAGCTGGGGCCACTGTGGGCATCATGATTGGAGTGTG
Rhesus CEACAM-5 (2001) CATAGTCAAGAACATCTCAGTCTCTCTGGGATTCAGCACTGGAAGTTCT---GGTCTCTCAGCTAGGGCTACTGTGGGCATCATAAATTGGAAATGCTG
(2101) 2101 2110 2121
Human CEACAM-5 (2089) GTTGGGGTTGCTCTGATATAG (SEQ ID NO:6)
Rhesus CEACAM-5 (2098) GTTGGGGTTGCTCTGATGATAG (SEQ ID NO:1)


```

FIG.6C

Human	CEACAM-5	(1)	1	10	20	30	40	50	60	70	80	90	100
Rhesus	CEACAM-5	(1)	MESPSAPPHRCIPWQRLITASLLTFWNPPTAKLT	TIESTPFNVAEQKEVLLLVHNL	PQHLFGYSW	MKGERVDGNRQITGV	IGTQATPGPAYSGREI						
Rhesus	CEACAM-5	(1)	MGSPSAPLHRWCIPWQRLITASLLTFWNPPTAQL	TTESRPFNVAEQKEVLLLAHNV	SQNLFGYIWKGERVDASRRIGSCVIR	TQQTTPGPAHSGRET							
Human	CEACAM-5	(101)	101	110	120	130	140	150	160	170	180	190	200
Rhesus	CEACAM-5	(101)	IYPNASLLIQNIQNDTGFTLHV	IKSDLVNEEATGQFRVYPEL	PKPSS	ISSNNSKPVEDKDAVAFTCEPETQ	DATYDAWVNNQSLPVS	PRQLQ	SNRNRTL				
Rhesus	CEACAM-5	(101)	IDFNASLLIHNVTQSDTGSYTIQV	IKEDLVNEEATGQFRVYPEL	PKPY	ISSNNSNPVEDKDAVAFTCEPETQ	DATTYLMWVNNQSLPVS	PRLELSSDNRTL					
Human	CEACAM-5	(201)	201	210	220	230	240	250	260	270	280	290	300
Rhesus	CEACAM-5	(201)	TLFNVTRNDTASYKCETQNPVSARRSDSV	ITLNVLYGPDAPTISPLNTSYRSGEN	NLSCHAA	SNPPAQYSWFVNGTFQ	QSTQELFIPNTTVNNSG	SYTQQ					
Rhesus	CEACAM-5	(201)	TVFNIPRNDTTSYKCETQNPVSRRSDP	VTNLNVLYGPDAPTISPLNTPYRAGEN	NLTCHAA	SNPTAQYFWFVNGTFQ	QSTQELFIPNTTVNNSG	SYMQQ					
Human	CEACAM-5	(301)	301	310	320	330	340	350	360	370	380	390	400
Rhesus	CEACAM-5	(301)	AHNSDTGLNRTIVITIVAEPPKPF	ITISNNPNVEDEDAVALTCEPEIQNT	TYLWVNNQSLPVS	PRQLQ	SDNRRTLTL	LSVTRNDVGP	YECGIONELS				
Rhesus	CEACAM-5	(301)	AHNSATGLNRTIVIAITVYAE	LPKYITISNNNP	IEDKDAVLTCEPETQ	DATTYLMWVNNQSLSV	SSRLELSDNRRTLTVFN	IPRNDTTF	YECETQNPVS				
Human	CEACAM-5	(401)	401	410	420	430	440	450	460	470	480	490	500
Rhesus	CEACAM-5	(401)	VDHSDPVILNVLYGPDPTISPSY	TYRPGVNL	SLSCHAA	SNPPAQYSWLIDGNI	QQHTQELFISNITEKNSGLY	TQANN	SNASGHSRTTVKTTIVSAEL				
Human	CEACAM-5	(501)	501	510	520	530	540	550	560	570	580	590	600
Rhesus	CEACAM-5	(501)	PKPSSISSNNSKPVEDKDAVAFT	CEPEAQNTIYLWVNGQSLPVS	PRQLQ	SNGNRRTL	TLFNVTRNDARAYV	CGIQNSV	SNRSDPVTLDVL	YGPDTPIISP			
Human	CEACAM-5	(601)	601	610	620	630	640	650	660	670	680	690	700
Rhesus	CEACAM-5	(601)	PDSSYLSGANLNL	SCHSASNP	SPQYSWRINGIPQ	HTQVLFIAKITPNNNGTYACFV	SNLATGRNNSIVK	SITVSAGTSPG---	LSAGATVGT	IMIGVLV			
Human	CEACAM-5	(701)	701	706									
Rhesus	CEACAM-5	(698)	GVALI	(SEQ ID NO:7)									
Rhesus	CEACAM-5	(701)	GVALM	(SEQ ID NO:2)									

FIG.7

FIG. 8



12/13

CELL MEDIATED IMMUNE RESPONSE AGAINST HUMAN CEA




FIG.9

13/13




FIG.10



## SEQUENCE LISTING

110> Luigi Aurisicchio

Fabio Palombo

Paolo Monaci

Nicola La Monica

Gennaro Ciliberto

Armin Lahm

120> RHESUS CARCINO EMBRYONIC ANTIGEN,  
NUCLEOTIDES ENCODING SAME, AND USES THEREOF

130> ITR0045 PCT

150> 60/447,203

151> 2003-02-13

160> 16

170> FastSEQ for Windows Version 4.0

210> 1

211> 2118

212> DNA

213> Macaca mulatta

400> 1

ggggtctc cctcagcccc tcttcacaga tgggtgcatcc cctggcagac gctcctgctc 60  
agcctcac ttctaacctt ctggaaccgg cccaccactg ccagctcac tattgaatcc 120  
gccgttca atgttgacaga ggggaaggag gttcttctac ttgccacaa tgtgtcccag 180  
tctttttg gctacatttg gtacaaggga gaaagagtgg atgccagccg tcgaattgga 240  
atgtgtaa taagaactca acaaattacc ccagggcccg cacacagcgg tcgagagaca 300

atagacttca atgcatccct gctgatccac aatgtcacc agagtgcac aggatcctac 360  
 accatacaag tcataaagga agatcttgat aatgaagaag caactggcca gttccgggta 420  
 taccgggagc tgcccaagcc ctacatctcc agcaacaact ccaaccccggt ggaggacaag 480  
 gatgctgtgg ccttaacctg tgaacctgag actcaggaca caacctacct gtggtgggta 540  
 aacaatcaga gcctcccgggt cagtcccagg ctggagctgt ccagtgcaca caggaccctc 600  
 actgtattca atattccaag aatgcacaca acatcctaca aatgtgaaac ccagaacca 660  
 gtgagtgtca gacgcagcga cccagtcacc ctgaacgtcc tctatggccc ggatgcgccc 720  
 accatttccc ctctaaacac accttacaga gcaggggaaa atctgaacct cacctgccac 780  
 gcagcctcta acccaactgc acagtacttt tggttgtca atgggacgtt ccagcaatcc 840  
 acacaagagc tctttatacc caacatcacc gtgaataata gcgatccta tatgtgcaa 900  
 gcccataact cagccactgg cctcaatagg accacagtca cggcgatcac agtctacgcg 960  
 gagctgcccc agccctacat caccagcaac aactccaacc ccatagagga caaggatgct 1020  
 gtgaccttaa cctgtgaacc tgagactcag gacacaacct acctgtgggt ggtaaacat 1080  
 cagagcctct cggctcagtc caggctggag ctgtccaatg acaacaggac cctcactgta 1140  
 ttcaatattc caagaaacga cacaacgttc tacgaatgtg agaccagaa cccagtgcgt 1200  
 gtcagacgca gcgaccagt caccctgaat gtcctctatg gcccgatgc gccaccatt 1260  
 tcccctctaa acacaccta cagagcagg gaaaatctga acctctctg ccacgcagcc 1320  
 tctaaccag ctgcacagta ctcttggtt gtcaatggga cgttcagca atccacaca 1380  
 gagctcttta tacccaacat caccgtgaat aatagcggat cctatatgtg ccaagcccat 1440  
 aactcagcca ctggcctcaa taggaccaca gtcacggcga tcacagtcta tgtggagctg 1500  
 cccaagccct acatctccag caacaactcc aaccccatag aggacaagga tgctgtgacc 1560  
 ttaacctgtg aacctgtggc tgagaacaca acctacctgt ggtgggtaaa caatcagagc 1620  
 ctctcggta gtcccaggct gcagctctcc aatggcaaca ggatcctcac tctactcagt 1680  
 gtcacacgga atgacacagg accctatgaa tgtggaatcc agaactcaga gagtgcataa 1740  
 cgcagtgcacc cagtcacct gaatgtcacc tatggcccag acaccccat catatcccc 1800  
 ccagacttgt ctaccgttc gggagcaaac ctcaacctct cctgccactc ggacttaac 1860  
 ccatccccgc agtattcttg gcttatcaat gggacactgc ggcaacacac acaagttctc 1920  
 ttatctcca aatcacatc aaacaatagc ggggcctatg cctgtttgt cttaactg 1980  
 gctaccggtc gcaataactc catagtcaag aacatctcag tctcctctgg cgattcagca 2040  
 cctggaagtt ctggtctctc agctagggt actgtcggca tcataattgg aatgctggt 2100  
 ggggtgctc tgatgtag 2118

&lt;210&gt; 2

&lt;211&gt; 705

&lt;212&gt; PRT

<213> Macaca mulatta

<400> 2

Met Gly Ser Pro Ser Ala Pro Leu His Arg Trp Cys Ile Pro Trp Gln  
 1            5            10            15  
 Thr Leu Leu Leu Thr Ala Ser Leu Leu Thr Phe Trp Asn Pro Pro Thr  
           20            25            30  
 Thr Ala Gln Leu Thr Ile Glu Ser Arg Pro Phe Asn Val Ala Glu Gly  
           35            40            45  
 Lys Glu Val Leu Leu Leu Ala His Asn Val Ser Gln Asn Leu Phe Gly  
           50            55            60  
 Tyr Ile Trp Tyr Lys Gly Glu Arg Val Asp Ala Ser Arg Arg Ile Gly  
 65            70            75            80  
 Ser Cys Val Ile Arg Thr Gln Gln Ile Thr Pro Gly Pro Ala His Ser  
           85            90            95  
 Gly Arg Glu Thr Ile Asp Phe Asn Ala Ser Leu Leu Ile His Asn Val  
           100            105            110  
 Thr Gln Ser Asp Thr Gly Ser Tyr Thr Ile Gln Val Ile Lys Glu Asp  
           115            120            125  
 Leu Val Asn Glu Glu Ala Thr Gly Gln Phe Arg Val Tyr Pro Glu Leu  
           130            135            140  
 Pro Lys Pro Tyr Ile Ser Ser Asn Asn Ser Asn Pro Val Glu Asp Lys  
 145            150            155            160  
 Asp Ala Val Ala Leu Thr Cys Glu Pro Glu Thr Gln Asp Thr Thr Tyr  
           165            170            175  
 Leu Trp Trp Val Asn Asn Gln Ser Leu Pro Val Ser Pro Arg Leu Glu  
           180            185            190  
 Leu Ser Ser Asp Asn Arg Thr Leu Thr Val Phe Asn Ile Pro Arg Asn  
           195            200            205  
 Asp Thr Thr Ser Tyr Lys Cys Glu Thr Gln Asn Pro Val Ser Val Arg  
           210            215            220  
 Arg Ser Asp Pro Val Thr Leu Asn Val Leu Tyr Gly Pro Asp Ala Pro  
 225            230            235            240  
 Thr Ile Ser Pro Leu Asn Thr Pro Tyr Arg Ala Gly Glu Asn Leu Asn  
           245            250            255

Leu Thr Cys His Ala Ala Ser Asn Pro Thr Ala Gln Tyr Phe Trp Phe  
 260 265 270  
 Val Asn Gly Thr Phe Gln Gln Ser Thr Gln Glu Leu Phe Ile Pro Asn  
 275 280 285  
 Ile Thr Val Asn Asn Ser Gly Ser Tyr Met Cys Gln Ala His Asn Ser  
 290 295 300  
 Ala Thr Gly Leu Asn Arg Thr Thr Val Thr Ala Ile Thr Val Tyr Ala  
 305 310 315 320  
 Glu Leu Pro Lys Pro Tyr Ile Thr Ser Asn Asn Ser Asn Pro Ile Glu  
 325 330 335  
 Asp Lys Asp Ala Val Thr Leu Thr Cys Glu Pro Glu Thr Gln Asp Thr  
 340 345 350  
 Thr Tyr Leu Trp Trp Val Asn Asn Gln Ser Leu Ser Val Ser Ser Arg  
 355 360 365  
 Leu Glu Leu Ser Asn Asp Asn Arg Thr Leu Thr Val Phe Asn Ile Pro  
 370 375 380  
 Arg Asn Asp Thr Thr Phe Tyr Glu Cys Glu Thr Gln Asn Pro Val Ser  
 385 390 395 400  
 Val Arg Arg Ser Asp Pro Val Thr Leu Asn Val Leu Tyr Gly Pro Asp  
 405 410 415  
 Ala Pro Thr Ile Ser Pro Leu Asn Thr Pro Tyr Arg Ala Gly Glu Asn  
 420 425 430  
 Leu Asn Leu Ser Cys His Ala Ala Ser Asn Pro Ala Ala Gln Tyr Ser  
 435 440 445  
 Trp Phe Val Asn Gly Thr Phe Gln Gln Ser Thr Gln Glu Leu Phe Ile  
 450 455 460  
 Pro Asn Ile Thr Val Asn Asn Ser Gly Ser Tyr Met Cys Gln Ala His  
 465 470 475 480  
 Asn Ser Ala Thr Gly Leu Asn Arg Thr Thr Val Thr Ala Ile Thr Val  
 485 490 495  
 Tyr Val Glu Leu Pro Lys Pro Tyr Ile Ser Ser Asn Asn Ser Asn Pro  
 500 505 510  
 Ile Glu Asp Lys Asp Ala Val Thr Leu Thr Cys Glu Pro Val Ala Glu  
 515 520 525  
 Asn Thr Thr Tyr Leu Trp Trp Val Asn Asn Gln Ser Leu Ser Val Ser

530            535            540  
 Pro Arg Leu Gln Leu Ser Asn Gly Asn Arg Ile Leu Thr Leu Leu Ser  
 545            550            555            560  
 Val Thr Arg Asn Asp Thr Gly Pro Tyr Glu Cys Gly Ile Gln Asn Ser  
               565            570            575  
 Glu Ser Ala Lys Arg Ser Asp Pro Val Thr Leu Asn Val Thr Tyr Gly  
               580            585            590  
 Pro Asp Thr Pro Ile Ile Ser Pro Pro Asp Leu Ser Tyr Arg Ser Gly  
               595            600            605  
 Ala Asn Leu Asn Leu Ser Cys His Ser Asp Ser Asn Pro Ser Pro Gln  
               610            615            620  
 Tyr Ser Trp Leu Ile Asn Gly Thr Leu Arg Gln His Thr Gln Val Leu  
 625            630            635            640  
 Phe Ile Ser Lys Ile Thr Ser Asn Asn Ser Gly Ala Tyr Ala Cys Phe  
               645            650            655  
 Val Ser Asn Leu Ala Thr Gly Arg Asn Asn Ser Ile Val Lys Asn Ile  
               660            665            670  
 Ser Val Ser Ser Gly Asp Ser Ala Pro Gly Ser Ser Gly Leu Ser Ala  
               675            680            685  
 Arg Ala Thr Val Gly Ile Ile Ile Gly Met Leu Val Gly Val Ala Leu  
               690            695            700  
 Met  
 705

<210> 3

<211> 32

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR Primer

<221> misc\_feature

<222> (0)...(0)

<223> S = C or G

<221> misc\_feature

<222> (0)...(0)

<223> R = A or G

<400> 3

ccgaattccg gacasagcag rcagcagrsa cc

32

<210> 4

<211> 37

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR Primer

<400> 4

ccgctcgagc ggctgctaca tcagagcaac cccaacc

37

<210> 5

<211> 2118

<212> DNA

<213> Macaca mulatta

<400> 5

atgggggtctc cctcagcccc tcttcacaga tgggtgatcc cctggcagac gctcctgctc 60  
 acagcctcac ttctaacctt ctggaaccgg cccaccactg cccagctcac tattgaatcc 120  
 aggccgttca atgttcgaga ggggaaggag gttcttctac ttgccacaa tgtgtcccag 180  
 aatctttttg gctacatttg gtacaaggga gaaagagtgg atgccagccg tcgaattgga 240  
 tcatgtgtaa taagaactca acaaattacc ccaggggccc cccagagcgg tcgagagaca 300  
 atagacttca atgcatccct gctgatccac aatgtcacc agagtgcac aggatcctac 360  
 accatacaag tcataaagga agatcttgtg aatgaagaag caactggcca gttccgggta 420  
 taccgggagc tgcccaagcc ctacatctcc agcaacaact ccaaccccggt ggaggacaag 480  
 gatgctgtgg ccttaacctg tgaacctgag actcaggaca caacctacct gtggtgggta 540

aacaatcaga gcctcccggg cagtcccagg ctggagctgt ccagtgacaa caggaccctc 600  
actgtattca atattccaag aatgacaca acatcctaca aatgtgaaac ccagaaccca 660  
gtgagtgtca gacgcagcga cccagtcacc ctgaacgtcc tctatggccc ggtatgcgccc 720  
accatttccc ctctaaacac acctacaga gcaggggaaa atctgaacct cacctgccac 780  
gcagcctcta acccaactgc acagtacttt tggttgtca atgggacgtt ccagcaatcc 840  
acacaagagc tctttatacc caacatcacc gtgaataata gcggatccta tatgtgcaa 900  
gcccataact cagccactgg cctcaatagg accacagtca cggcgatcac agtctacgcg 960  
gagctgcccga agccctacat caccagcaac aactccaacc ccatagagga caaggatgct 1020  
gtgaccttaa cctgtgaacc tgagactcag gacacaacct acctgtggtg ggtaacaat 1080  
cagagcctct cggtcagttc caggctggag ctgtccaatg acaacaggac cctcactgta 1140  
ttcaatattc caagaaacga cacaacgttc tacgaatgtg agaccagaa cccagtgaat 1200  
gtcagacgca gcgaccaggt caccctgaat gtcctctatg gcccgatgc gccaccatt 1260  
tcccctctaa acacacctta cagagcaggg gaaaatctga acctctcctg ccacgcagcc 1320  
tctaaccag ctgcacagta ctttgggtt gtcaatggga cgttccagca atccacaaa 1380  
gagctcttta taccacat caccgtgaat aatagcggat cctatatgtg ccaagccat 1440  
aactcagcca ctggcctcaa taggaccaca gtcacggcga tcacagtcta tgtggagctg 1500  
cccaagccct acatctccag caacaactcc aaccccatag aggacaagga tgcgtgacc 1560  
ttaacctgtg aacctgtggc tgagaacaca acctacctgt ggtgggtaaa caatcagagc 1620  
ctctcggtca gtcccaggct gcagctctcc aatggcaaca ggatcctcac tctactcagt 1680  
gtcacacgga atgacacagg accctatgaa tgtggaatcc agaactcaga gattgcaaaa 1740  
cgcagtgacc cagtcacct gaatgtcacc tatggcccag acaccccat catatcccc 1800  
ccagactgtg cttaccgttc gggagcaaac ctcaacctct cctgccactc ggactctaac 1860  
ccatccccgc agtattcttg gcttatcaat gggacactgc ggcaacacac acaagttctc 1920  
tttatctcca aatcacatc aaacaataac ggggcctatg cctgtttgt ctctaactg 1980  
gctaccggtc gcaataactc catagtcaag aacatctcag tctctctgg cgattcagca 2040  
cctggaagtt ctggtctctc agctagggct actgtcggca tcataattgg aatgctggtt 2100  
ggggttgctc tgatgtag 2118

<210> 6

<211> 2109

<212> DNA

<213> Homo sapiens

<400> 6

atggagtctc cctcggcccc tccccacaga tggatcatcc cctggcagag gctcctgctc 60

acagcctcac ttctaaccct ctggaacccg cccaccactg ccaagctcac tattgaatcc 120  
 acgccgttca atgtcgaga ggggaaggag gtgctctac ttgtccaca tctgcccag 180  
 catctttttg gctacagctg gtacaaaggt gaaagagtgg atggcaaccg tcaaattata 240  
 ggatatgtaa taggaactca acaagctacc ccaggggccc catacagtgg tcgagagata 300  
 atatacccca atgcatccct gctgatccag aacatcatcc agaatgacac aggattctac 360  
 accctacacg tcafaaagtc agatcttgtg aatgaagaag caactggcca gtccgggta 420  
 taccgggagc tgcccaagcc ctccatctcc agcaacaact ccaaaccgt ggaggacaag 480  
 gatgctgtgg ccttcacctg tgaacctgag actcaggacg caacctacct gtggtgggta 540  
 aacaatcaga gcctcccggt cagtcccagg ctgcagctgt ccaatggcaa caggaccctc 600  
 actctattca atgtcacaag aatgacaca gcaagctaca aatgtgaac ccagaaccca 660  
 gtgagtcca ggcgcagtga ttcatctc ctgaatgtcc tctatggccc ggatgcccc 720  
 accatttccc cttaaacac atcttacaga tcaggggaaa atctgaacct ctctgccat 780  
 gcagcctcta acccactgc acagtactct tggttgtca atgggacttt ccagcaatcc 840  
 acccaagagc tctttatccc caacatcact gtgaataata gtggatccta tacgtgcca 900  
 gcccataact cagacactgg cctcaatagg accacagtca cgacgatcac agtctatgca 960  
 gagccacca aaccttcat caccagcaac aactccaacc ccgtggagga tgaggatgct 1020  
 gtagccttaa cctgtgaacc tgagattcag aacacaacct acctgtgtg ggtaaataat 1080  
 cagagcctcc cggtcagtcc caggctgcag ctgtccaatg acaacaggac cctcactcta 1140  
 ctcatgtca caaggaatga ttaggagccc tatgagtgtg gaatccagaa cgaattaagt 1200  
 gtgaccaca ggcacccagt catctgaat gtctctatg gccagacga cccaccatt 1260  
 tccccctcat acacctatta ccgtccagg gtgaacctca gcctctctg ccatgcagcc 1320  
 tctaaccac ctgcacagta ttctggctg attgatggga acatccagca acacacaaa 1380  
 gagctcttta tctccaacat cactgagaag aacagcggac tctatactg ccaggccaat 1440  
 aactcagcca gtggccacag caggactaca gtcaagacaa tcacagtctc tcgggagctg 1500  
 ccaagccct ccactccag caacaactcc aaaccgtgg aggacaagga tgctgtggcc 1560  
 ttacctgtg aacctgaggc tcagaacaca acctacctgt ggtgggtaa tggcagagc 1620  
 ctcccagta gtccaggct gcagctgtcc aatggcaaca ggaccctcac tctattcaat 1680  
 gtcaagaa atgacgaag agcctatgta tgtggaatcc agaactcagt gagtcaaac 1740  
 cgcagtgacc cagtcacct ggatgtctc tatgggccg acacccccat catttcccc 1800  
 ccagactcgt ctaccttcc gggagcgaac ctcaacctct cctgccactc ggccttaac 1860  
 ccatccccgc agtattcttg gcgtatcaat gggataccgc agcaacacac acaagttctc 1920  
 tttatcgcca aatcacgcc aaataataac gggacatatg cctgtttgt cttaacttg 1980  
 gctactggcc gcaataatc catagtcaag agcatcacag tctctgcatc tggaacttct 2040  
 cctggtctct cagctggggc cactgtcggc atcatgattg gagtgtgtgt tggggttct 2100  
 ctgatatag

2109



&lt;210&gt; 7

&lt;211&gt; 708

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 7

Met Glu Ser Pro Ser Ala Pro Pro His Arg Trp Cys Ile Pro Trp Gln

1 5 10 15

Arg Leu Leu Leu Thr Ala Ser Leu Leu Thr Phe Trp Asn Pro Pro Thr

20 25 30

Thr Ala Lys Leu Thr Ile Glu Ser Thr Pro Phe Asn Val Ala Glu Gly

35 40 45

Lys Glu Val Leu Leu Leu Val His Asn Leu Pro Gln His Leu Phe Gly

50 55 60

Tyr Ser Trp Tyr Lys Gly Glu Arg Val Asp Gly Asn Arg Gln Ile Ile

65 70 75 80

Gly Tyr Val Ile Gly Thr Gln Gln Ala Thr Pro Gly Pro Ala Tyr Ser

85 90 95

Gly Arg Glu Ile Ile Tyr Pro Asn Ala Ser Leu Leu Ile Gln Asn Ile

100 105 110

Ile Gln Asn Asp Thr Gly Phe Tyr Thr Leu His Val Ile Lys Ser Asp

115 120 125

Leu Val Asn Glu Glu Ala Thr Gly Gln Phe Arg Val Tyr Pro Glu Leu

130 135 140

Pro Lys Pro Ser Ile Ser Ser Asn Asn Ser Lys Pro Val Glu Asp Lys

145 150 155 160

Asp Ala Val Ala Phe Thr Cys Glu Pro Glu Thr Gln Asp Ala Thr Tyr

165 170 175

Leu Trp Trp Val Asn Asn Gln Ser Leu Pro Val Ser Pro Arg Leu Gln

180 185 190

Leu Ser Asn Gly Asn Arg Thr Leu Thr Leu Phe Asn Val Thr Arg Asn

195 200 205

Asp Thr Ala Ser Tyr Lys Cys Glu Thr Gln Asn Pro Val Ser Ala Arg

210 215 220

Arg Ser Asp Ser Val Ile Leu Asn Val Leu Tyr Gly Pro Asp Ala Pro  
 225            230            235            240  
 Thr Ile Ser Pro Leu Asn Thr Ser Tyr Arg Ser Gly Glu Asn Leu Asn  
              245            250            255  
 Leu Ser Cys His Ala Ala Ser Asn Pro Pro Ala Gln Tyr Ser Trp Phe  
              260            265            270  
 Val Asn Gly Thr Phe Gln Gln Ser Thr Gln Glu Leu Phe Ile Pro Asn  
              275            280            285  
 Ile Thr Val Asn Asn Ser Gly Ser Tyr Thr Cys Gln Ala His Asn Ser  
              290            295            300  
 Asp Thr Gly Leu Asn Arg Thr Thr Val Thr Thr Ile Thr Val Tyr Ala  
 305            310            315            320  
 Glu Pro Pro Lys Pro Phe Ile Thr Ser Asn Asn Ser Asn Pro Val Glu  
              325            330            335  
 Asp Glu Asp Ala Val Ala Leu Thr Cys Glu Pro Glu Ile Gln Asn Thr  
              340            345            350  
 Thr Tyr Leu Trp Trp Val Asn Asn Gln Ser Leu Pro Val Ser Pro Arg  
              355            360            365  
 Leu Gln Leu Ser Asn Asp Asn Arg Thr Leu Thr Leu Leu Ser Val Thr  
              370            375            380  
 Arg Asn Asp Val Gly Pro Tyr Glu Cys Gly Ile Gln Asn Glu Leu Ser  
 385            390            395            400  
 Val Asp His Ser Asp Pro Val Ile Leu Asn Val Leu Tyr Gly Pro Asp  
              405            410            415  
 Asp Pro Thr Ile Ser Pro Ser Tyr Thr Tyr Tyr Arg Pro Gly Val Asn  
              420            425            430  
 Leu Ser Leu Ser Cys His Ala Ala Ser Asn Pro Pro Ala Gln Tyr Ser  
              435            440            445  
 Trp Leu Ile Asp Gly Asn Ile Gln Gln His Thr Gln Glu Leu Phe Ile  
              450            455            460  
 Ser Asn Ile Thr Glu Lys Asn Ser Gly Leu Tyr Thr Cys Gln Ala Asn  
 465            470            475            480  
 Asn Ser Ala Ser Gly His Ser Arg Thr Thr Val Lys Thr Ile Thr Val  
              485            490            495  
 Ser Ala Glu Leu Pro Lys Pro Ser Ile Ser Ser Asn Asn Ser Lys Pro

500            505            510  
 Val Glu Asp Lys Asp Ala Val Ala Phe Thr Cys Glu Pro Glu Ala Gln  
 515            520            525  
 Asn Thr Thr Tyr Leu Trp Trp Val Asn Gly Gln Ser Leu Pro Val Ser  
 530            535            540  
 Pro Arg Leu Gln Leu Ser Asn Gly Asn Arg Thr Leu Thr Leu Phe Asn  
 545            550            555            560  
 Val Thr Arg Asn Asp Ala Arg Ala Tyr Val Cys Gly Ile Gln Asn Ser  
 565            570            575  
 Val Ser Ala Asn Arg Ser Asp Pro Val Thr Leu Asp Val Leu Tyr Gly  
 580            585            590  
 Pro Asp Thr Pro Ile Ile Ser Pro Pro Asp Ser Ser Tyr Leu Ser Gly  
 595            600            605  
 Ala Asn Leu Asn Leu Ser Cys His Ser Ala Ser Asn Pro Ser Pro Gln  
 610            615            620  
 Tyr Ser Trp Arg Ile Asn Gly Ile Pro Gln Gln His Thr Gln Val Leu  
 625            630            635            640  
 Phe Ile Ala Lys Ile Thr Pro Asn Asn Asn Gly Thr Tyr Ala Cys Phe  
 645            650            655  
 Val Ser Asn Leu Ala Thr Gly Arg Asn Asn Ser Ile Val Lys Ser Ile  
 660            665            670  
 Thr Val Ser Ala Ser Gly Thr Ser Pro Gly Leu Ser Ala Gly Ala Thr  
 675            680            685  
 Val Gly Ile Met Ile Gly Val Leu Val Gly Val Ala Leu Ile Ser Glu  
 690            695            700  
 Gln Ile Asp Asn  
 705

&lt;210&gt; 8

&lt;211&gt; 705

&lt;212&gt; PRT

<213> *Macaca mulatta*

&lt;400&gt; 8

Met Gly Ser Pro Ser Ala Pro Leu His Arg Trp Cys Ile Pro Trp Gln  
 1            5            10            15  
 Thr Leu Leu Leu Thr Ala Ser Leu Leu Thr Phe Trp Asn Pro Pro Thr  
           20            25            30  
 Thr Ala Gln Leu Thr Ile Glu Ser Arg Pro Phe Asn Val Ala Glu Gly  
           35            40            45  
 Lys Glu Val Leu Leu Leu Ala His Asn Val Ser Gln Asn Leu Phe Gly  
           50            55            60  
 Tyr Ile Trp Tyr Lys Gly Glu Arg Val Asp Ala Ser Arg Arg Ile Gly  
 65            70            75            80  
 Ser Cys Val Ile Arg Thr Gln Gln Ile Thr Pro Gly Pro Ala His Ser  
           85            90            95  
 Gly Arg Glu Thr Ile Asp Phe Asn Ala Ser Leu Leu Ile His Asn Val  
           100            105            110  
 Thr Gln Ser Asp Thr Gly Ser Tyr Thr Ile Gln Val Ile Lys Glu Asp  
           115            120            125  
 Leu Val Asn Glu Glu Ala Thr Gly Gln Phe Arg Val Tyr Pro Glu Leu  
           130            135            140  
 Pro Lys Pro Tyr Ile Ser Ser Asn Asn Ser Asn Pro Val Glu Asp Lys  
 145            150            155            160  
 Asp Ala Val Ala Leu Thr Cys Glu Pro Glu Thr Gln Asp Thr Thr Tyr  
           165            170            175  
 Leu Trp Trp Val Asn Asn Gln Ser Leu Pro Val Ser Pro Arg Leu Glu  
           180            185            190  
 Leu Ser Ser Asp Asn Arg Thr Leu Thr Val Phe Asn Ile Pro Arg Asn  
           195            200            205  
 Asp Thr Thr Ser Tyr Lys Cys Glu Thr Gln Asn Pro Val Ser Val Arg  
           210            215            220  
 Arg Ser Asp Pro Val Thr Leu Asn Val Leu Tyr Gly Pro Asp Ala Pro  
 225            230            235            240  
 Thr Ile Ser Pro Leu Asn Thr Pro Tyr Arg Ala Gly Glu Asn Leu Asn  
           245            250            255  
 Leu Thr Cys His Ala Ala Ser Asn Pro Thr Ala Gln Tyr Phe Trp Phe  
           260            265            270  
 Val Asn Gly Thr Phe Gln Gln Ser Thr Gln Glu Leu Phe Ile Pro Asn

275            280            285  
 Ile Thr Val Asn Asn Ser Gly Ser Tyr Met Cys Gln Ala His Asn Ser  
 290            295            300  
 Ala Thr Gly Leu Asn Arg Thr Thr Val Thr Ala Ile Thr Val Tyr Ala  
 305            310            315            320  
 Glu Leu Pro Lys Pro Tyr Ile Thr Ser Asn Asn Ser Asn Pro Ile Glu  
 325            330            335  
 Asp Lys Asp Ala Val Thr Leu Thr Cys Glu Pro Glu Thr Gln Asp Thr  
 340            345            350  
 Thr Tyr Leu Trp Trp Val Asn Asn Gln Ser Leu Ser Val Ser Ser Arg  
 355            360            365  
 Leu Glu Leu Ser Asn Asp Asn Arg Thr Leu Thr Val Phe Asn Ile Pro  
 370            375            380  
 Arg Asn Asp Thr Thr Phe Tyr Glu Cys Glu Thr Gln Asn Pro Val Ser  
 385            390            395            400  
 Val Arg Arg Ser Asp Pro Val Thr Leu Asn Val Leu Tyr Gly Pro Asp  
 405            410            415  
 Ala Pro Thr Ile Ser Pro Leu Asn Thr Pro Tyr Arg Ala Gly Glu Asn  
 420            425            430  
 Leu Asn Leu Ser Cys His Ala Ala Ser Asn Pro Ala Ala Gln Tyr Phe  
 435            440            445  
 Trp Phe Val Asn Gly Thr Phe Gln Gln Ser Thr Gln Glu Leu Phe Ile  
 450            455            460  
 Pro Asn Ile Thr Val Asn Asn Ser Gly Ser Tyr Met Cys Gln Ala His  
 465            470            475            480  
 Asn Ser Ala Thr Gly Leu Asn Arg Thr Thr Val Thr Ala Ile Thr Val  
 485            490            495  
 Tyr Val Glu Leu Pro Lys Pro Tyr Ile Ser Ser Asn Asn Ser Asn Pro  
 500            505            510  
 Ile Glu Asp Lys Asp Ala Val Thr Leu Thr Cys Glu Pro Val Ala Glu  
 515            520            525  
 Asn Thr Thr Tyr Leu Trp Trp Val Asn Asn Gln Ser Leu Ser Val Ser  
 530            535            540  
 Pro Arg Leu Gln Leu Ser Asn Gly Asn Arg Ile Leu Thr Leu Leu Ser  
 545            550            555            560

Val Thr Arg Asn Asp Thr Gly Pro Tyr Glu Cys Gly Ile Gln Asn Ser  
           565              570              575  
 Glu Ser Ala Lys Arg Ser Asp Pro Val Thr Leu Asn Val Thr Tyr Gly  
           580              585              590  
 Pro Asp Thr Pro Ile Ile Ser Pro Pro Asp Leu Ser Tyr Arg Ser Gly  
           595              600              605  
 Ala Asn Leu Asn Leu Ser Cys His Ser Asp Ser Asn Pro Ser Pro Gln  
           610              615              620  
 Tyr Ser Trp Leu Ile Asn Gly Thr Leu Arg Gln His Thr Gln Val Leu  
           625              630              635              640  
 Phe Ile Ser Lys Ile Thr Ser Asn Asn Asn Gly Ala Tyr Ala Cys Phe  
           645              650              655  
 Val Ser Asn Leu Ala Thr Gly Arg Asn Asn Ser Ile Val Lys Asn Ile  
           660              665              670  
 Ser Val Ser Ser Gly Asp Ser Ala Pro Gly Ser Ser Gly Leu Ser Ala  
           675              680              685  
 Arg Ala Thr Val Gly Ile Ile Ile Gly Met Leu Val Gly Val Ala Leu  
           690              695              700  
 Met  
 705

&lt;210&gt; 9

&lt;211&gt; 81

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; consensus sequence

&lt;400&gt; 9

agcggttctg gagccaagc tcttctccac agaggaggac agagcaggca gcagagacca 60  
 tggggccccc ctcagccct c

81

&lt;210&gt; 10

<211> 81

<212> DNA

<213> Homo sapiens

<400> 10

aacgttctg gaactcaagc tcttctccac agaggaggac agagcagaca gcagagacca 60  
tggagtctcc ctggcccct c 81

<210> 11

<211> 80

<212> DNA

<213> Homo sapiens

<400> 11

agcattcctg gagtcaagc tctctacaaa gaggtggaca gagaagacag cagagacat 60  
gggaccccc tcagcccctc 80

<210> 12

<211> 81

<212> DNA

<213> Homo sapiens

<400> 12

agcgttctg gagcccaagc tctctccac aggtgaagac agggccagca ggagacacca 60  
tggggcacct ctgacccca c 81

<210> 13

<211> 54

<212> DNA

<213> Homo sapiens

<400> 13

gcacagagga gaacacgcag gcagcagaga ccatggggcc catctcagcc cctt 54

<210> 14

<211> 78

<212> DNA

<213> Homo sapiens

<400> 14

agagttcctg gagccccaag ctcttctcca cagaggacaa gcaggcagca gagaccatgg 60  
gttcccccttc agcctgtc 78

<210> 15

<211> 76

<212> DNA

<213> Homo sapiens

- 16 -

<400> 15

tcctggagcc caggctcttt tccacagagg aggaaagagc aggcagcaga gaccatgggg 60  
ccccctcag cccctc 76

<210> 16

<211> 76

<212> DNA

<213> Homo sapiens

<400> 16

agcgttcctg gagcccagct cctctccaca gaccacaagc acccagcaga gaccatgggc 60  
ccccctcag ccgctc 76



## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N15/63 C12N15/861 C12N1/12 C07K14/705 C12N5/10  
A61K48/00

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

EMBASE, BIOSIS, CHEM ABS Data, EPO-Internal, WPI Data, EMBL

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>US 5 274 087 A (KAMARCK MICHAEL E ET AL) 28 December 1993 (1993-12-28) cited in the application column 20, line 55 -column 21, line 68 --- -/-</p>	1-34

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

## \* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the International filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

17 June 2004

Date of mailing of the international search report

06/08/2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Barnas, C

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>WHEELER C W ET AL: "Safety and immunogenicity of a recombinant vaccinia virus vaccine expressing a 70kDa fragment of the human carcinoembryonic antigen in a nonhuman primate"</p> <p>PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL, vol. 36, no. 0, 1995, page 366 XP001181916</p> <p>Eighty-sixth Annual Meeting of the American Association for Cancer Research; Toronto, Ontario, Canada; March 18-22, 1995, 1995</p> <p>ISSN: 0197-016X</p> <p>abstract</p>	1-34
A	<p>IRVINE K ET AL: "CHARACTERIZATION OF IMMUNOLOGICAL RESPONSES USING A CEA RECOMBINANT VACCINIA VIRUS IN NON-HUMAN PRIMATES"</p> <p>PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL, vol. 33, 1992, page 334 XP001181917</p> <p>83RD ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, SAN DIEGO, CALIFORNIA, USA, MAY, 1992</p> <p>ISSN: 0197-016X</p> <p>abstract</p>	1-34
A	<p>KANTOR J ET AL: "Immunogenicity and safety of a recombinant vaccinia virus vaccine expressing the carcinoembryonic antigen gene in a nonhuman primate"</p> <p>CANCER RESEARCH, vol. 52, no. 24, 1992, pages 6917-6925, XP000605381</p> <p>ISSN: 0008-5472</p> <p>abstract</p> <p>page 6920, left-hand column, paragraph 2</p> <p>-page 6923, right-hand column, paragraph 1</p>	1-34
A	<p>JANTSCHKEFF P ET AL: "SEARCH FOR CARCINOEMBRYONIC ANTIGEN-LIKE MOLECULES IN POLYMORPHONUCLEAR LEUKOCYTES OF NON-HUMAN PRIMATES USING MONOCLONAL ANTIBODIES"</p> <p>ARCHIV FUER GESCHWULSTFORSCHUNG, vol. 56, no. 2, 1986, pages 113-116, XP001181929</p> <p>ISSN: 0003-911X</p> <p>abstract</p> <p>page 8, paragraph 1</p>	1-34

-/--

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 01/30382 A (AVENTIS PASTEUR ;BARBER BRIAN (CA); BERINSTEIN NEIL (CA); MOINGEON) 3 May 2001 (2001-05-03) page 2, line 12 -page 3, line 3 example 1 claims 1,2,4,5	1-34

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/EP2004/001181

## Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 20-24, 29-34  
because they relate to subject matter not required to be searched by this Authority, namely:  
see FURTHER INFORMATION sheet PCT/ISA/210
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

Continuation of Box II.1

Although claims 20-24, 29-34 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

---

Continuation of Box II.1

Claims Nos.: 20-24, 29-34

Rule 39.1(iv) PCT - Method for treatment of the human or animal body by therapy

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/EP2004/001181

Box No. 1 Nucleotide and/or amino acid sequence(s) (Continuation of item 1.b of the first sheet)

1. With regard to any nucleotide and/or amino acid sequence disclosed in the international application and necessary to the claimed invention, the international search was carried out on the basis of:

a. type of material

☒

a sequence listing

☐

table(s) related to the sequence listing

b. format of material

☒

in written format

☒

in computer readable form

c. time of filing/furnishing

☒

contained in the international application as filed

☐

filed together with the international application in computer readable form

☐

furnished subsequently to this Authority for the purpose of search

2. ☐ In addition, in the case that more than one version or copy of a sequence listing and/or table relating thereto has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished.

3. Additional comments:

Patent document cited in search report		Publication date	Patent family member(s)		Publication date
US 5274087	A	28-12-1993	US	5571710 A	05-11-1996
			US	5843761 A	01-12-1998
			AT	96168 T	15-11-1993
			AU	598573 B2	28-06-1990
			AU	7686887 A	24-03-1988
			CA	1341440 C	30-09-2003
			DE	3787864 D1	25-11-1993
			DE	3787864 T2	10-02-1994
			DK	420487 A	14-02-1988
			EP	0263933 A1	20-04-1988
			ES	2059330 T3	16-11-1994
			FI	873478 A	14-02-1988
			IE	60279 B1	29-06-1994
			IL	83484 A	31-01-1993
			JP	9136900 A	27-05-1997
			NZ	221385 A	25-06-1991
			US	6342583 B1	29-01-2002
			US	5122599 A	16-06-1992
			US	6013772 A	11-01-2000
			US	6022958 A	08-02-2000
			US	5231009 A	27-07-1993
			JP	3253609 B2	04-02-2002
			JP	63119681 A	24-05-1988
			ZA	8705951 A	19-02-1988
WO 0130382	A	03-05-2001	AU	1013601 A	08-05-2001
			AU	1013701 A	08-05-2001
			WO	0130382 A1	03-05-2001
			WO	0130847 A1	03-05-2001
			CA	2388301 A1	03-05-2001
			CA	2388337 A1	03-05-2001
			EP	1227837 A1	07-08-2002
			EP	1228095 A1	07-08-2002
			JP	2003512437 T	02-04-2003
			JP	2003512829 T	08-04-2003